Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis

Abstract

The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.

Claims

1. A method comprising administering to a subject suffering from or susceptible to amyotrophic lateral sclerosis (ALS) an effective amount of a compound of a formula: ##STR00223## or a pharmaceutically acceptable salt thereof, wherein: each R is independently hydrogen, halogen, optionally substituted C.sub.1-6 aliphatic, optionally substituted phenyl, optionally substituted benzyl, or two R on the same carbon are taken together to form a 5-6 membered saturated, partially saturated, or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R.sup.1, R.sup.2, and R.sup.3 are each independently R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, NRC(O)R, NRC(O)(CO)R, NRC(O)N(R).sub.2, NRC(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2, or an optionally substituted 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; L is a valence bond or a bivalent saturated or partially unsaturated, branched or unbranched C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of L are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2, and wherein L is optionally substituted with 1-4 R groups, wherein two R on the same carbon or on adjacent carbons are optionally taken together to form a 3-6 membered saturated spirocyclic or fused monocyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Ring A is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; m is 0-5; each R.sup.a is independently R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, NRC(O)R, NRC(O)(CO)R, NRC(O)N(R).sub.2, NRC(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2, or: two R.sup.a on adjacent carbons are taken together to form an optionally substituted 3-12 membered saturated, partially unsaturated, or aryl fused ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: at least one R.sup.a is independently ##STR00224## wherein Q is a valence bond or a bivalent optionally substituted saturated or partially unsaturated, branched or unbranched C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of Q are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2; Ring B is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; n is 0-5; each R.sup.b is independently R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, NRC(O)R, NRC(O)C(O)R, N(R)C(O)N(R).sub.2, N(R)C(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2; and R.sup.4 and R.sup.4 are each independently R, or R.sup.4 and R.sup.4 are taken together to form an alkenylene optionally substituted with one or two R.sup.c groups; wherein each R.sup.c is independently R, OR, CN, NO.sub.2, SR, S(O)R, SO.sub.2R, C(O)R, CO.sub.2R, C(O)N(R).sub.2, NRC(O)R, NRC(O)N(R).sub.2, NRSO.sub.2R, N(R).sub.2, or wherein R.sup.c is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein R.sup.c is optionally substituted with p occurrences of R.sup.d, wherein: p is 0 to 5; and each R.sup.d is independently R, OR, CN, C(R).sub.3, NO.sub.2, SR, S(O)R, SO.sub.2R, C(O)R, CO.sub.2R, C(O)N(R).sub.2, NRC(O)R, NRC(O)N(R).sub.2, NRSO.sub.2R, or N(R).sub.2, thereby reducing the severity or incidence of one or more symptoms of ALS or delaying onset thereof.

2. The method according to claim 1 wherein L is a bivalent saturated branched or unbranched C.sub.1-10 hydrocarbon chain.

3. The method according to claim 2, wherein Ring A is a 5-6 membered aryl ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

4. The method according to claim 3, wherein Ring A is of the formula: ##STR00225## wherein m is 0-5.

5. The method according to claim 2, wherein 1 methylene unit of L is replaced by NR, O, S, C(O), or C(O)O.

6. The method according to claim 5, wherein L is selected from a bivalent saturated C.sub.2-C.sub.3 hydrocarbon chain and a bivalent saturated C.sub.2-C.sub.3 hydrocarbon chain wherein 1 methylene unit of L is replaced by O, and wherein L is substituted with 1-2 R groups.

7. The method according to claim 6, wherein Ring A is of the formula: ##STR00226## wherein m is 1-5.

8. The method according to claim 7, wherein each R.sup.a is independently fluorine, chlorine, methyl, ethyl, propyl, butyl, methoxy, propoxy, butoxy or trifluoromethyl.

9. The method according to claim 8, wherein m is 1-2.

10. The method according to claim 9, wherein Ring A is of the formula: ##STR00227##

11. The method according to claim 10, wherein R.sup.3 is selected from H, methyl and trifluoromethyl.

12. The method according to claim 1, of any of the formulae: ##STR00228## ##STR00229## ##STR00230## ##STR00231## ##STR00232## ##STR00233## ##STR00234## ##STR00235## ##STR00236## or a stereochemically isomeric form thereof.

13. The method according to claim 1 wherein a symptom of ALS is abnormal aggregation of an SODI protein.

14. The method of claim 13 wherein said subject is a human.

15. A method comprising administering to a subject suffering from or susceptible to amyotrophic lateral sclerosis (ALS) an effective amount of a compound of formula I-a or I-b: ##STR00237## or a pharmaceutically acceptable salt thereof, wherein: each R is independently hydrogen, halogen, or optionally substituted C.sub.1-6 aliphatic; R.sup.1, R.sup.2, and R.sup.3 are each independently R, or OR; L is a bivalent saturated branched or unbranched C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of L are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2, and wherein L is optionally substituted with 1-4 R groups, wherein two R on the same carbon or on adjacent carbons are optionally taken together to form a 3-6 membered saturated spirocyclic or fused monocyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Ring A is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; m is 0-5; and each R.sup.a is independently R, or OR, thereby reducing the severity or incidence of one or more symptoms of ALS or delaying onset thereof.

16. The method according to claim 15, of the formula: ##STR00238## where each of R, R.sup.1, R.sup.2 and R.sup.3 is independently selected from H, C.sub.1-C.sub.4 alkyl and trifluoromethyl.

17. The method according to claim 16, wherein each of R.sup.1, R.sup.2 and R.sup.3 is H.

18. The method according to claim 17, wherein each R taken together forms a 3-membered ring.

19. The method according to claim 18, wherein Ring A is substituted phenyl.

20. The method according to claim 19, selected from ##STR00239##

21. The method according to claim 15 of the formula: ##STR00240##

22. The method according to claim 21, wherein R.sup.1 and R.sup.2 are H, and R.sup.3 and each R is independently selected from H, CH.sub.3 and CF.sub.3.

23. The method according to claim 22, wherein Ring A is substituted phenyl.

24. The method according to claim 23, selected from ##STR00241##

25. The method according to claim 15 wherein a symptom of ALS is abnormal aggregation of an SODI protein.

26. The method of claim 25 wherein said subject is a human.

27. A method comprising administering to a subject suffering from or susceptible to amyotrophic lateral sclerosis (ALS) an effective amount of a compound of a formula: ##STR00242## or a pharmaceutically acceptable salt thereof, wherein: each R is independently hydrogen, halogen, or optionally halo-substituted C.sub.1-6 aliphatic; L is a bivalent saturated unbranched C.sub.1-6 hydrocarbon chain, wherein 1-3 methylene units of L are optionally and independently replaced by NR or O, and wherein L is optionally substituted with 1-4 R groups, wherein two R on the same carbon or on adjacent carbons are optionally taken together to form a 3-6 membered saturated spirocyclic or fused monocyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Ring A is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; m is 0-5; and each R.sup.a is independently R or OR, thereby reducing the severity or incidence of one or more symptoms of ALS or delaying onset thereof.

28. The method according to claim 27, wherein L is selected from a bivalent saturated C.sub.2-C.sub.3 hydrocarbon chain and a bivalent saturated C.sub.2-C.sub.3 hydrocarbon chain wherein 1 methylene unit of L is replaced by O, and wherein L is substituted with 1-2 R groups.

29. The method according to claim 28, wherein L is a bivalent saturated C.sub.2 hydrocarbon chain, and Ring A is substituted phenyl.

30. The method according to claim 29, selected from ##STR00243##

31. The method according to claim 28, wherein L is a bivalent saturated C.sub.2 hydrocarbon chain wherein one methylene unit is replaced by O, and Ring A is substituted phenyl.

32. The method according to claim 31, wherein L is substituted with a trifluoromethyl group.

33. The method according to claim 32, selected from ##STR00244##

34. The method of claim 27 in a pharmaceutical composition comprising a pharmaceutically-acceptable excipient.

35. The method according to claim 27 wherein a symptom of ALS is abnormal aggregation of an SODI protein.

36. The method of claim 35 wherein said subject is a human.

Description

BRIEF DESCRIPTION OF THE DRAWING

(1) FIGS. 1A-C. Proteasome inhibition is selectively toxic to PC12 cells expressing mutant G93A SOD1. Cell survival was determined using the viability stain calcein-AM. At 24 hr, treatment with 100 nM MG132 shows no toxicity against any of the cell lines although aggregates are seen in G85R SOD1 and G93A SOD1 cell lines (1A). Treatment with 100 nM MG132 is selectively toxic to the G93A SOD1 cell line after 48 hours (1B). Washing of the cells at 24 hours to remove the compound does not reverse toxicity to the G93A SOD 1 cell line suggesting that an irreversible toxic event, potentially related the aggregation of G93A SOD1, has been triggered prior to wash out (1C).

(2) FIG. 2. Radicicol protects PC12 cells expressing mutant G93A SOD1 from the toxic effects of proteasome inhibitor MG132.

(3) FIGS. 3A-F. Mutant but not wild type SOD 1 aggregates in cells treated with the proteasome inhibitor MG132. Fluorescence micrographs of PC12 cells expressing YFP tagged wild type (WT), G93A mutant (G93A), and G85R mutant (G85R) SOD1 proteins (3A-C). The micrographs show the effects of treating cells with 200 nM MG132 for 24 h (untreated cells are shown in insets on left, 3D-F respectively). The wild type SOD1 expressing cells are unaffected while cells expressing mutant SOD1 show large perinuclear aggregates.

(4) FIGS. 4A-D. Radicicol decreases mutant SOD1 aggregation induced by proteasome inhibitor MG132. Fluorescence micrographs of PC12 cells expressing YFP tagged G93A SOD1 (left) or G85R SOD1 (right) proteins. The cells were untreated, treated with 200 nM MG132 to induce protein aggregation (4A and 4C, respectively), or co-treated with MG132 and radicicol for 24 h (4B and 4D respectively). Without radicicol treatment, cells show large perinuclear aggregates. The aggregates are reduced in radicicol-treated cells. While the behavior of the two cell lines is generally similar, G85R SOD1 cells show brighter aggregates and more contrast between the aggregates and the cytoplasm.

(5) FIGS. 5A-E. Automated detection of mutant SOD1 aggregates. Left: compound microscope fluorescence micrographs of the same G85R SOD1 cells using GFP filters set to image the SOD1-YFP aggregates (5A) and the TR1TC filter set to image iT-WGA plasma membrane (5C). Right: Aggregates detection from the Cellomics Arrayscan 3.5 using spot detector software to image cells with Image-iT in channel 1 (5D) and SOD1-YFP aggregates in channel 2 (5E). Data are expressed (5B) as spot count (aggregates) per object (cell).

(6) FIG. 6. Compound dose response studies for primary cortical neuron penetration.

DETAILED DESCRIPTION OF THE INVENTION

Cyclohexan-1,3-dione Compounds (CHD Compounds)

(7) The present invention provides cyclohexan-1,3-dione compounds (herein referred to as CHD compounds), compositions, and methods for treating patients suffering from or susceptible to amyotrophic lateral sclerosis (ALS) or other neurodegenerative diseases. Without wishing to be bound by any particular theory or mechanism of action, provided CHD compounds and compositions thereof are useful in inhibiting or reversing abnormal protein aggregation or reducing the toxicity of protein aggregation (e.g., SOD1). In certain embodiments, provided CHD compounds and compositions thereof are useful in modulating proteosome function. The present invention provides methods for treating a subject suffering from or susceptible to ALS or other neurodegenerative disease including the step of administering to the subject a therapeutically effective amount of a provided CHD compound or composition thereof. In certain embodiments, the subject is a mammal (e.g., a human).

(8) In one aspect, the present invention provides a compound or composition comprising a compound of formula I:

(9) ##STR00005##
or a pharmaceutically acceptable salt thereof, wherein: T.sup.1 is a valence bond or a bivalent saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of T.sup.1 are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2, and wherein T.sup.1 is optionally substituted with 1-4 R groups; each R is independently hydrogen, halogen, optionally substituted C.sub.1-6 aliphatic, optionally substituted phenyl, optionally substituted benzyl, or two R on the same nitrogen are taken together to form a 5-6 membered saturated, partially saturated, or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; T.sup.2 is a valence bond or a bivalent saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of T.sup.2 are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2, and wherein T.sup.2 is optionally substituted with 1-4 R groups; R.sup.1, R.sup.2, and R.sup.3 are each independently R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, NRC(O)R, NRC(O)(CO)R, NRC(O)N(R).sub.2, NRC(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2, or an optionally substituted 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R.sup.3 is R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, NRC(O)R, NRC(O)(CO)R, NRC(O)N(R).sub.2, NRC(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2, or

(10) ##STR00006## L is a valence bond or a bivalent saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of L are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2, and wherein L is optionally substituted with 1-4 R groups, wherein: two R on the same carbon or on adjacent carbons are optionally taken together to form a 3-6 membered saturated spirocyclic or fused monocyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Ring A is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; m is 0-5; each R.sup.a is independently R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, NRC(O)R, NRC(O)(CO)R, NRC(O)N(R).sub.2, NRC(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2, or: two R.sup.a on adjacent carbons are taken together to form an optionally substituted 3-12 membered saturated, partially unsaturated, or aryl fused ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: at least one R.sup.a is independently

(11) ##STR00007##
wherein: Q is a valence bond or a bivalent optionally substituted saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of Q are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2; Ring B is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; n is 0-5; each R.sup.b is independently R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, NRC(O)R, NRC(O)C(O)R, N(R)C(O)N(R).sub.2, N(R)C(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2; R.sup.4 and R.sup.4 are each independently R, or: R.sup.4 and R.sup.4 are taken together to form an alkenylene optionally substituted with one or two R.sup.c groups; each R.sup.c is independently R, OR, CN, NO.sub.2, SR, S(O)R, SO.sub.2R, C(O)R, CO.sub.2R, C(O)N(R).sub.2, NRC(O)R, NRC(O)N(R).sub.2, NRSO.sub.2R, N(R).sub.2, or wherein R.sup.c is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein R.sup.c is optionally substituted with p occurrences of R.sup.d, wherein: p is 0 to 5; each R.sup.d is independently R, OR, CN, C(R).sub.3, NO.sub.2, SR, S(O)R, SO.sub.2R, C(O)R, CO.sub.2R, C(O)N(R).sub.2, NRC(O)R, NRC(O)N(R).sub.2, NRSO.sub.2R, or N(R).sub.2.

(12) As defined generally above and herein, T.sup.1 is a valence bond or a bivalent saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of T.sup.1 are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2, and wherein T.sup.1 is optionally substituted with 1-4 R groups. In some embodiments, T.sup.1 is a valence bond. In some embodiments, T.sup.1 is a bivalent saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of T.sup.1 are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2. In certain embodiments, T.sup.1 is a bivalent saturated or partially unsaturated C.sub.1-5 hydrocarbon chain, wherein 1-2 methylene units of T.sup.1 are optionally and independently replaced by NR, O, or -, S. In certain embodiments, T.sup.1 is a bivalent saturated C.sub.1-5 hydrocarbon chain, wherein 1 methylene unit of T.sup.1 is optionally and independently replaced by NR, O, or -, S. In certain embodiments, T is a bivalent saturated C.sub.2-4 hydrocarbon chain, wherein 1 methylene unit of T.sup.1 is replaced by O. In certain embodiments, T.sup.1 is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T.sup.1 is replaced by O.

(13) As defined generally above and herein, T.sup.2 is a valence bond or a bivalent saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of T.sup.2 are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2, and wherein T.sup.2 is optionally substituted with 1-4 R groups. In some embodiments, T.sup.2 is a valence bond. In some embodiments, T.sup.2 is a bivalent saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of T.sup.2 are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2. In certain embodiments, T.sup.2 is a bivalent saturated or partially unsaturated C.sub.1-5 hydrocarbon chain, wherein 1-2 methylene units of T.sup.2 are optionally and independently replaced by NR, O, or -, S. In certain embodiments, T.sup.2 is a bivalent saturated C.sub.1-5 hydrocarbon chain, wherein 1 methylene unit of T.sup.2 is optionally and independently replaced by NR, O, or -, S. In certain embodiments, T.sup.2 is a bivalent saturated C.sub.2-4 hydrocarbon chain, wherein 1 methylene unit of T.sup.2 is replaced by O. In certain embodiments, T.sup.2 is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T.sup.2 is replaced by O.

(14) In some embodiments, at least one of T.sup.1 and/or T.sup.2 is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T.sup.1 and/or T.sup.2 is replaced by O. In some embodiments, T.sup.1 and T.sup.2 are both bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T and T.sup.2 is replaced by O. In some embodiments, T.sup.1 is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T.sup.1 is replaced by O and wherein R.sup.1 is optionally substituted phenyl. In some embodiments, T.sup.2 is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T.sup.2 is replaced by O and wherein R.sup.2 is optionally substituted phenyl. In certain embodiments, at least one of T.sup.1 and/or T.sup.2 is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T and/or T.sup.2 is replaced by O and wherein at least one of R.sup.3, R.sup.3, R.sup.4, and/or R.sup.4 is hydrogen. In certain embodiments, at least one of T.sup.1 and/or T.sup.2 is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T.sup.1 and/or T.sup.2 is replaced by O and wherein at least two of R.sup.3, R.sup.3, R.sup.4, and/or R.sup.4 are hydrogen. In certain embodiments, at least one of T.sup.1 and/or T.sup.2 is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T.sup.1 and/or T.sup.2 is replaced by O and wherein at least three of R.sup.3, R.sup.3, R.sup.4, and/or R.sup.4 are hydrogen. In certain embodiments, at least one of T.sup.1 and/or T.sup.2 is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of T.sup.1 and/or T.sup.2 is replaced by O and wherein R.sup.3, R.sup.3, R.sup.4, and R.sup.4 are hydrogen.

(15) As defined generally above and herein, R.sup.1, R.sup.2, and R.sup.3 are each independently R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, NRC(O)R, NRC(O)(CO)R, NRC(O)N(R).sub.2, NRC(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2, or an optionally substituted 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

(16) In some embodiments, R.sup.1 is R, OR, SR, or N(R).sub.2. In certain embodiments, R.sup.1 is halogen or R. In certain embodiments, R.sup.1 is hydrogen, methyl, ethyl, propyl, or butyl. In certain embodiments, R.sup.1 is hydrogen. In certain embodiments, R.sup.1 is methyl.

(17) In some embodiments, R.sup.1 is an optionally substituted 3-8 membered saturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 3-6 membered saturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 5-6 membered saturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

(18) In some embodiments, R.sup.1 is an optionally substituted 3-8 membered partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 3-6 membered partially unsaturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 5-6 membered partially unsaturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

(19) In some embodiments, R.sup.1 is an optionally substituted 5-6 membered aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 5-6 membered aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 5 membered aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 6 membered aryl ring having 1-3 nitrogens. In some embodiments, R.sup.1 is an optionally substituted phenyl. In certain embodiments, R.sup.1 is unsubstituted phenyl.

(20) In some embodiments, R.sup.1 is an optionally substituted 8-10 membered saturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 8-10 membered saturated bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 8-10 membered saturated bicyclic carbocycle.

(21) In some embodiments, R.sup.1 is an optionally substituted 8-10 membered partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 8-10 membered partially unsaturated bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 8-10 membered partially unsaturated carbocycle.

(22) In some embodiments, R.sup.1 is an optionally substituted 9-10 membered aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 9-10 membered aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 9 membered aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is an optionally substituted 10 membered aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.1 is optionally substituted naphthyl.

(23) In some embodiments, R.sup.2 is R, OR, SR, or N(R).sub.2. In certain embodiments, R.sup.2 is halogen or R. In certain embodiments, R.sup.2 is hydrogen, methyl, ethyl, propyl, or butyl. In certain embodiments, R.sup.2 is hydrogen. In certain embodiments, R.sup.2 is methyl.

(24) In some embodiments, R.sup.2 is an optionally substituted 3-8 membered saturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 3-6 membered saturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 5-6 membered saturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

(25) In some embodiments, R.sup.2 is an optionally substituted 3-8 membered partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 3-6 membered partially unsaturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 5-6 membered partially unsaturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

(26) In some embodiments, R.sup.2 is an optionally substituted 5-6 membered aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 5-6 membered aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 5 membered aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 6 membered aryl ring having 1-3 nitrogens. In some embodiments, R.sup.2 is an optionally substituted phenyl. In certain embodiments, R.sup.2 is unsubstituted phenyl.

(27) In some embodiments, R.sup.2 is an optionally substituted 8-10 membered saturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 8-10 membered saturated bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 8-10 membered saturated bicyclic carbocycle.

(28) In some embodiments, R.sup.2 is an optionally substituted 8-10 membered partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 8-10 membered partially unsaturated bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 8-10 membered partially unsaturated carbocycle.

(29) In some embodiments, R.sup.2 is an optionally substituted 9-10 membered aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 9-10 membered aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 9 membered aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is an optionally substituted 10 membered aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.2 is optionally substituted naphthyl.

(30) In some embodiments, R.sup.3 is R, OR, SR, or N(R).sub.2. In certain embodiments, R.sup.3 is halogen or R. In certain embodiments, R.sup.3 is hydrogen, methyl, ethyl, propyl, or butyl. In certain embodiments, R.sup.3 is hydrogen. In certain embodiments, R.sup.3 is methyl.

(31) In some embodiments, R.sup.3 is an optionally substituted 3-8 membered saturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 3-6 membered saturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 5-6 membered saturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

(32) In some embodiments, R.sup.3 is an optionally substituted 3-8 membered partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 3-6 membered partially unsaturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 5-6 membered partially unsaturated monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

(33) In some embodiments, R.sup.3 is an optionally substituted 5-6 membered aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 5-6 membered aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 5 membered aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 6 membered aryl ring having 1-3 nitrogens. In some embodiments, R.sup.3 is an optionally substituted phenyl. In certain embodiments, R.sup.3 is unsubstituted phenyl.

(34) In some embodiments, R.sup.3 is an optionally substituted 8-10 membered saturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 8-10 membered saturated bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 8-10 membered saturated bicyclic carbocycle.

(35) In some embodiments, R.sup.3 is an optionally substituted 8-10 membered partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 8-10 membered partially unsaturated bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 8-10 membered partially unsaturated carbocycle.

(36) In some embodiments, R.sup.3 is an optionally substituted 9-10 membered aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 9-10 membered aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 9 membered aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is an optionally substituted 10 membered aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R.sup.3 is optionally substituted naphthyl.

(37) In certain embodiments, at least one of R.sup.1, R.sup.2, and R.sup.3 is hydrogen. In certain embodiments, at least two of R.sup.1, R.sup.2, and R.sup.3 are hydrogen. In certain embodiments, each of R.sup.1, R.sup.2, and R.sup.3 are hydrogen. In certain embodiments, R.sup.1 and R.sup.2 are hydrogen and R.sup.3 is R. In certain embodiments, R.sup.1 and R.sup.2 are hydrogen and R.sup.3 is methyl.

(38) As defined generally above and herein, R.sup.3 is R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, NRC(O)R, NRC(O)(CO)R, NRC(O)N(R).sub.2, NRC(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2, or

(39) ##STR00008##
In some embodiments, R.sup.3 is R. In some embodiments, R.sup.3 is hydrogen. In some embodiments, R.sup.3, is

(40) ##STR00009##

(41) As defined generally above and herein, L is a valence bond or a bivalent saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of L are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2, and wherein L is optionally substituted with 1-4 R groups, wherein: two R on the same carbon or on adjacent carbons are optionally taken together to form a 3-6 membered saturated spirocyclic or fused monocyclic ring containing 0-2 heteroatoms selected from nitrogen, oxygen, and sulfur.

(42) In some embodiments, L is a valence bond.

(43) In some embodiments, L is a bivalent saturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of L are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2. In some embodiments, L is optionally substituted with 1-4 R groups. In some embodiments, L is a bivalent saturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of L are optionally and independently replaced by NR, O, S, C(O), or C(O)O, and wherein L is optionally substituted with 1-4 R groups. In some embodiments, L is a bivalent saturated C.sub.1-10 hydrocarbon chain, wherein 1 methylene unit of L is replaced by NR, O, or S, and wherein L is optionally substituted with 1-4 R groups. In some embodiments, L is a bivalent saturated C.sub.1-6 hydrocarbon chain, wherein 1 methylene unit of L is replaced by NR, O, or S, and wherein L is optionally substituted with 1-4 R groups.

(44) In some embodiments, L is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of L is optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2. In some embodiments, L is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of L is optionally and independently replaced by NR, O, S, C(O), or C(O)O, and wherein L is optionally substituted with 1-3 R groups. In some embodiments, L is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of L is replaced by NR, O, or S, and wherein L is optionally substituted with 1-3 R groups. In some embodiments, L is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of L is replaced by O and wherein L is optionally substituted with 1-2 R groups. In some embodiments, L is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of L is replaced by O and wherein L is optionally substituted with 1-2 methyl groups. In some embodiments, L is a bivalent saturated C.sub.2 hydrocarbon chain, wherein 1 methylene unit of L is replaced by O and wherein L is substituted with one methyl group.

(45) In some embodiments, L is a bivalent saturated C.sub.1 hydrocarbon chain, wherein L is optionally substituted with 1-2 R groups, and wherein each R is independently halogen or optionally substituted C.sub.1-6 aliphatic. In some embodiments, L is a bivalent saturated C.sub.2 hydrocarbon chain, wherein L is optionally substituted with 1-2 R groups. In some embodiments, L is a bivalent saturated C.sub.2 hydrocarbon chain, wherein L is optionally substituted with 1-2 R groups, and wherein each R is independently halogen or optionally substituted C.sub.1-6 aliphatic. In some embodiments, L is a bivalent saturated C.sub.3 hydrocarbon chain, wherein L is optionally substituted with 1-6 R groups. In some embodiments, L is a bivalent saturated C.sub.3 hydrocarbon chain, wherein L is optionally substituted with 1-6 R groups, and wherein each R is independently halogen or optionally substituted C.sub.1-6 aliphatic. In some embodiments, L is a bivalent saturated C.sub.3 hydrocarbon chain wherein 1 methylene unit of L is optionally replaced by O, and wherein L is optionally substituted with 1-4 R groups. In some embodiments, L is a bivalent saturated C.sub.4 hydrocarbon chain, wherein L is optionally substituted with 1-4 R groups. In some embodiments, L is a bivalent saturated C.sub.4 hydrocarbon chain wherein 1 methylene unit of L is optionally replaced by O. In certain embodiments, L is a bivalent saturated C.sub.1 hydrocarbon chain substituted with 1-2 R groups, wherein each R is independently C.sub.1-6 aliphatic. In certain embodiments, L is a bivalent saturated C.sub.1 hydrocarbon chain substituted with 1-2 R groups, wherein each R is independently fluorine or methyl. In certain embodiments, L is a bivalent saturated C.sub.2 hydrocarbon chain substituted with 1-2 R groups, wherein each R is independently fluorine, methyl, or optionally substituted phenyl.

(46) In certain embodiments, two R on the same carbon or on adjacent carbons of L are optionally taken together to form a 3-6 membered saturated spirocyclic or fused monocyclic ring containing 0-2 heteroatoms selected from nitrogen, oxygen, and sulfur. In certain embodiments, two R on the same carbon of L are optionally taken together to form a 3-6 membered saturated spirocyclic ring containing 0-2 heteroatoms selected from nitrogen, oxygen, and sulfur. In certain embodiments, two R on adjacent carbons of L are optionally taken together to form a 3-6 membered fused monocyclic ring containing 0-2 heteroatoms selected from nitrogen, oxygen, and sulfur. In certain embodiments, two R on adjacent carbons of L are optionally taken together to form a 3 membered fused monocyclic ring containing 0-1 heteroatoms selected from nitrogen, oxygen, and sulfur. In certain embodiments, two R on adjacent carbons of L are optionally taken together to form a cyclopropylene moiety.

(47) Exemplary such fused monocyclic cycloalkylene moieties formed when two R on adjacent carbons of L are taken together are of any one of the following formulae:

(48) ##STR00010##
It would be apparent to one of skill in the art that all possible stereoisomers of the above-depicted and above-described fused monocyclic cycloalkylene moieties are contemplated herein. In some embodiments, one or more methylene units of the above-depicted cycloalkylene moieties are replaced by NR, O, or S. In some embodiments, one or more methylene units of the above-depicted cycloalkylene moieties are substituted with 1-4 R groups. In some embodiments, one or more methylene units of the above-depicted cycloalkylene moieties are substituted with 1-2 R groups.

(49) As defined generally above and herein, Ring A is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

(50) In some embodiments, Ring A is a 3-8 membered saturated monocyclic ring optionally containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is a 3-8 membered saturated monocyclic carbocycle. In some embodiments, Ring A is a 5-6 membered saturated monocyclic ring optionally containing 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is a 5-6 membered saturated monocyclic carbocycle.

(51) In some embodiments, Ring A is a 3-8 membered partially unsaturated monocyclic ring optionally containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is a 3-8 membered partially unsaturated monocyclic carbocycle. In some embodiments, Ring A is a 5-6 membered partially unsaturated monocyclic ring optionally containing 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is a 5-6 membered partially unsaturated monocyclic carbocycle.

(52) In some embodiments, Ring A is a 5-6 membered aryl ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is a 5 membered aryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is a 6 membered aryl ring containing 0-4 nitrogens. In certain embodiments, Ring A is phenyl. In certain embodiments, Ring A is furanyl, thiophenyl, or pyrrolyl.

(53) In some embodiments, Ring A is of the formula:

(54) ##STR00011##

(55) In some embodiments, Ring A is of any one of the formulae:

(56) ##STR00012##

(57) In some embodiments, Ring A is of any one of the formulae:

(58) ##STR00013##

(59) In some embodiments, Ring A is of any one of the formulae:

(60) ##STR00014##

(61) In some embodiments, Ring A is of any one of the formulae:

(62) ##STR00015##

(63) In some embodiments, Ring A is of the formula:

(64) ##STR00016##

(65) In some embodiments, m is 0-5. In certain embodiments, m is 1-4. In certain embodiments, m is 1-2. In certain embodiments, m is 1.

(66) In some embodiments, R.sup.3 is

(67) ##STR00017##
wherein

(68) ##STR00018##
is of any one of the following formulae:

(69) ##STR00019##

(70) As defined generally above and herein, each R.sup.a is independently R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, N(R)C(O)R, N(R)C(O)C(O)R, N(R)C(O)N(R).sub.2, N(R)C(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2, or: two R.sup.a on adjacent carbons are taken together to form an optionally substituted 3-12 membered saturated, partially unsaturated, or aryl fused ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: at least one R.sup.a is independently

(71) ##STR00020##

(72) In some embodiments, each R.sup.a is independently R, OR, SR, SO.sub.2R, C(O)R, OC(O)R, CO.sub.2R, C(O)N(R).sub.2, N(R)C(O)R, N(R).sub.2, or

(73) ##STR00021##

(74) In some embodiments, each R.sup.a is R, wherein R is optionally substituted C.sub.1-6 aliphatic. In certain embodiments, each R.sup.a is independently methyl, ethyl, propyl, butyl, or trifluoromethyl. In certain embodiments, at least one R.sup.a is independently C.sub.1-6 aliphatic optionally substituted with fluorine. In certain embodiments, at least two R.sup.a are independently C.sub.1-6 aliphatic optionally substituted with fluorine. Exemplary such groups include CF.sub.3, CF.sub.2H, CFH.sub.2, CF.sub.2CF.sub.3, CF.sub.2CHF.sub.2, CF.sub.2CH.sub.2F, CF.sub.2CH.sub.3, CHFCH.sub.3, CHFCH.sub.2F, CHFCHF.sub.2, and CHFCF.sub.3.

(75) In certain embodiments, at least one R.sup.a is independently halogen. In certain embodiments, at least one R.sup.a is independently fluorine. In certain embodiments, at least one R.sup.a is independently chlorine. In certain embodiments, at least one R.sup.a is independently bromine. In certain embodiments, at least two R.sup.a are independently halogen. In certain embodiments, at least two R.sup.a are independently fluorine. In certain embodiments, at least two R.sup.a are independently chlorine. In certain embodiments, at least two R.sup.a are independently bromine. In certain embodiments, at least three R.sup.a are independently halogen.

(76) In some embodiments, at least one R.sup.a is independently OR. In some embodiments, at least two R.sup.a are independently OR. In some embodiments, at least three R.sup.a are independently OR. In certain embodiments wherein one or more R.sup.a are independently OR, each R is independently hydrogen or optionally substituted C.sub.1-6 aliphatic. Exemplary OR groups include OH, OMe, OEt, OBn, OCF.sub.3, OCF.sub.2H, OCFH.sub.2, OCF.sub.2CF.sub.3, OCF.sub.2CHF.sub.2, OCF.sub.2CH.sub.2F, OCF.sub.2CH.sub.3, OCHFCH.sub.3, OCHFCH.sub.2F, OCHFCHF.sub.2, and OCHFCF.sub.3.

(77) In some embodiments, at least one R.sup.a is independently C(O)R or OC(O)R. In some embodiments, at least two R.sup.a are independently C(O)R or OC(O)R. In some embodiments, at least three R.sup.a are independently C(O)R or OC(O)R. In certain embodiments wherein one or more R.sup.a are independently C(O)R or OC(O)R, each R is independently hydrogen or optionally substituted C.sub.1-6 aliphatic.

(78) In some embodiments, at least one R.sup.a is independently SR. In some embodiments, at least two R.sup.a are independently SR. In some embodiments, at least three R.sup.a are independently SR. In certain embodiments wherein one or more R.sup.a are independently SR, each R is independently hydrogen or optionally substituted C.sub.1-6 aliphatic. Exemplary SR groups include SH, SMe, and SEt. In some embodiments, at least one R.sup.a is independently S(O)R. In some embodiments, at least two R.sup.a are independently S(O)R. In some embodiments, at least one R.sup.a is independently SO.sub.2R. In some embodiments, at least two R.sup.a are independently SO.sub.2R. In certain embodiments wherein one or more R.sup.a are S(O)R or SO.sub.2R, each R is independently hydrogen or optionally substituted C.sub.1-6 aliphatic.

(79) In some embodiments, at least one R.sup.a is independently N(R).sub.2. In some embodiments, at least two R.sup.a are independently N(R).sub.2. In some embodiments, at least three R.sup.a are independently N(R).sub.2. In certain embodiments wherein one or more R.sup.a are independently N(R).sub.2, each R is independently hydrogen, optionally substituted C.sub.1-6 aliphatic, or phenyl. Exemplary N(R).sub.2 groups NH.sub.2, NHMe, NHEt, NMe.sub.2, and NEt.sub.2, and N(Ph).sub.2.

(80) In certain embodiments, two R.sup.a on adjacent carbons are taken together to form an optionally substituted 3-12 membered saturated, partially unsaturated, or aryl fused ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, two R.sup.a on adjacent carbons are taken together to form an optionally substituted 3-12 membered fused carbocycle. In certain embodiments, two R.sup.a on adjacent carbons are taken together to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl fused ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, two R.sup.a on adjacent carbons are taken together to form an optionally substituted 5-8 membered fused carbocycle. In certain embodiments, two R.sup.a on adjacent carbons are taken together to form optionally substituted fused phenyl. In certain embodiments, two R.sup.a on adjacent carbons are taken together to form an optionally substituted 6 membered fused aryl ring containing nitrogen. In certain embodiments, two R.sup.a on adjacent carbons are taken together to form an optionally substituted 7 membered partially unsaturated or aryl fused ring containing nitrogen.

(81) In some embodiments, Ring A is of any of the following formulae:

(82) ##STR00022## ##STR00023##

(83) In certain embodiments, Ring A is of the formula:

(84) ##STR00024##

(85) In some embodiments, at least one R.sup.a is independently.

(86) ##STR00025##
In some embodiments, at least two R.sup.a are independently

(87) ##STR00026##

(88) As defined generally above and herein, Q is a valence bond or a bivalent optionally substituted saturated or partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of Q are optionally and independently replaced by NR, N(R)C(O), C(O)N(R), N(R)SO.sub.2, SO.sub.2N(R), O, C(O), OC(O), C(O)O, S, S(O) or SO.sub.2.

(89) In some embodiments, Q is a valence bond.

(90) In some embodiments, Q is a bivalent optionally substituted saturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of Q are optionally and independently replaced by NR, O, C(O), OC(O), C(O)O, or S. In some embodiments, Q is a bivalent optionally substituted partially unsaturated C.sub.1-10 hydrocarbon chain, wherein 1-3 methylene units of Q are optionally and independently replaced by NR, O, C(O), OC(O), C(O)O, or S. In certain embodiments, Q is a bivalent optionally substituted saturated C.sub.1-6 hydrocarbon chain, wherein 1-3 methylene units of Q are optionally and independently replaced by NR, O, C(O), OC(O), C(O)O, or S. In certain embodiments, Q is a bivalent optionally substituted saturated C.sub.1-6 hydrocarbon chain, wherein 1 methylene unit of Q is optionally and independently replaced by NR, O, C(O), OC(O), C(O)O, or S. In certain embodiments, Q is a bivalent optionally substituted saturated C.sub.1-6 hydrocarbon chain, wherein 1 methylene unit of Q is optionally replaced by NR. In certain embodiments, Q is a bivalent optionally substituted saturated C.sub.1-6 hydrocarbon chain, wherein 1 methylene unit of Q is optionally replaced by O. In certain embodiments, Q is a bivalent optionally substituted saturated C.sub.1-6 hydrocarbon chain, wherein 1 methylene unit of Q is optionally replaced by S. In certain embodiments, Q is a bivalent optionally substituted saturated C.sub.1-6 hydrocarbon chain, wherein 2 methylene units of Q are each independently replaced by NR, O, and S. In certain embodiments, Q is a bivalent optionally substituted saturated C.sub.1-6 hydrocarbon chain, wherein 2 methylene units of Q are replaced by O. In some embodiments, Q is a bivalent optionally substituted saturated C.sub.1 hydrocarbon chain, wherein 1 methylene unit is optionally replaced by NR. In some embodiments, Q is a bivalent optionally substituted saturated C.sub.1 hydrocarbon chain, wherein 1 methylene unit is optionally replaced by O. In some embodiments, Q is a bivalent optionally substituted saturated C.sub.1 hydrocarbon chain, wherein 1 methylene unit is optionally replaced by S.

(91) As defined generally above and herein, Ring B is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

(92) In some embodiments, Ring B is a 3-8 membered saturated monocyclic ring optionally containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is a 3-8 membered saturated monocyclic carbocycle. In some embodiments, Ring B is a 5-6 membered saturated monocyclic ring optionally containing 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is a 5-6 membered saturated monocyclic carbocycle. In some embodiments, Ring B is a 6 membered saturated monocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is a 6 membered saturated monocyclic ring containing 2 nitrogen atoms.

(93) In some embodiments, Ring B is a 3-8 membered partially unsaturated monocyclic ring optionally containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is a 3-8 membered partially unsaturated monocyclic carbocycle. In some embodiments, Ring B is a 5-6 membered partially unsaturated monocyclic ring optionally containing 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is a 5-6 membered partially unsaturated monocyclic carbocycle.

(94) In some embodiments, Ring B is a 5-6 membered aryl ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is a 5 membered aryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is a 6 membered aryl ring containing 0-4 nitrogens. In certain embodiments, Ring B is phenyl.

(95) In some embodiments, Ring B is of the formula:

(96) ##STR00027##

(97) In some embodiments, Ring B is of one of the formulae:

(98) ##STR00028##

(99) In some embodiments, Ring B is of one of the formulae:

(100) ##STR00029##

(101) In some embodiments, Ring B is of one of the formulae:

(102) ##STR00030##

(103) In some embodiments, Ring B is of one of the formulae:

(104) ##STR00031##

(105) In some embodiments, Ring B is of the formula:

(106) ##STR00032##

(107) As defined generally above and herein, n is 0-5. In some embodiments, n is 0, 1, 2, 3, 4 or 5. In certain embodiments, n is 0, 1, or 2.

(108) As defined generally above and herein, each R.sup.b is independently R, OR, SR, S(O)R, SO.sub.2R, OSO.sub.2R, N(R).sub.2, N(R)C(O)R, N(R)C(O)C(O)R, N(R)C(O)N(R).sub.2, N(R)C(O)OR, N(R)S(O)R, N(R)SO.sub.2R, N(R)SO.sub.2OR, C(O)R, C(O)OR, OC(O)R, OC(O)OR, C(O)N(R).sub.2, OC(O)N(R).sub.2.

(109) In some embodiments, each R.sup.b is independently R, OR, SR, SO.sub.2R, C(O)R, OC(O)R, CO.sub.2R, C(O)N(R).sub.2, N(R)C(O)R, or N(R).sub.2.

(110) In some embodiments, each R.sup.b is independently R, wherein each R is optionally substituted C.sub.1-6 aliphatic. In certain embodiments, each R.sup.b is independently methyl, ethyl, propyl, butyl, or trifluoromethyl. In certain embodiments, at least one R.sup.b is independently C.sub.1-6 aliphatic optionally substituted with fluorine. In certain embodiments, at least two R.sup.b are independently C.sub.1-6 aliphatic optionally substituted with fluorine. Exemplary such groups include CF.sub.3, CF.sub.2H, CFH.sub.2, CF.sub.2CF.sub.3, CF.sub.2CHF.sub.2, CF.sub.2CH.sub.2F, CF.sub.2CH.sub.3, CHFCH.sub.3, CHFCH.sub.2F, CHFCHF.sub.2, and CHFCF.sub.3.

(111) In certain embodiments, at least one R.sup.b is independently halogen. In certain embodiments, at least one R.sup.b is independently fluorine. In certain embodiments, at least one R.sup.b is independently chlorine. In certain embodiments, at least one R.sup.b is independently bromine. In certain embodiments, at least two R.sup.b are independently halogen. In certain embodiments, at least two R.sup.b are independently fluorine. In certain embodiments, at least two R.sup.b are independently chlorine. In certain embodiments, at least two R.sup.b are independently bromine. In certain embodiments, at least three R.sup.b are independently halogen.

(112) In some embodiments, at least one R.sup.b is independently OR. In some embodiments, at least two R.sup.b are independently OR. In some embodiments, at least three R.sup.b are independently OR. In certain embodiments wherein one or more R.sup.b are each independently OR, each R is independently hydrogen or optionally substituted C.sub.1-6 aliphatic. Exemplary OR groups include OH, OMe, OEt, OBn, OCF.sub.3, OCF.sub.2H, OCFH.sub.2, OCF.sub.2CF.sub.3, OCF.sub.2CHF.sub.2, OCF.sub.2CH.sub.2F, OCF.sub.2CH.sub.3, OCHFCH.sub.3, OCHFCH.sub.2F, OCHFCHF.sub.2, and OCHFCF.sub.3.

(113) In some embodiments, at least one R.sup.b is independently C(O)R or O(CO)R. In certain embodiments, at least one R.sup.b is independently C(O)R or O(CO)R. In some embodiments, at least two R.sup.b are independently C(O)R or O(CO)R. In some embodiments, at least three R.sup.b are independently C(O)R or O(CO)R. In certain embodiments wherein one or more R.sup.b are independently C(O)R or O(CO)R, each R is independently hydrogen or optionally substituted C.sub.1-6 aliphatic.

(114) In some embodiments, at least one R.sup.b is independently SR. In some embodiments, at least two R.sup.b are independently SR. In some embodiments, at least three R.sup.b are independently SR. In certain embodiments wherein one or more R.sup.b are independently SR, each R is independently hydrogen or optionally substituted C.sub.1-6 aliphatic. Exemplary SR groups include SH, SMe, and SEt.

(115) In some embodiments, at least one R.sup.b is independently S(O)R. In some embodiments, at least two R.sup.b are independently S(O)R. In some embodiments, at least one R.sup.b is independently SO.sub.2R. In certain embodiments, at least two R.sup.b are independently SO.sub.2R. In certain embodiments wherein one or more R.sup.b is S(O)R or SO.sub.2R, each R is independently hydrogen or optionally substituted C.sub.1-6 aliphatic.

(116) In some embodiments, at least one R.sup.b is independently N(R).sub.2. In some embodiments, at least two R.sup.b are independently N(R).sub.2, In some embodiments, at least three R.sup.b are independently N(R).sub.2. In certain embodiments wherein one or more R.sup.b are independently N(R).sub.2, each R is independently hydrogen or optionally substituted C.sub.1-6 aliphatic. Exemplary N(R).sub.2 groups NH.sub.2, NHMe, NHEt, NME.sub.2, and NEt.sub.2.

(117) In some embodiments, Ring B is of any of the following formulae:

(118) ##STR00033##

(119) As defined generally above and herein, R.sup.4 and R.sup.4 are each independently R, or: R.sup.4 and R.sup.4 are taken together to form an alkenylene optionally substituted with one or two R.sup.c groups; each R.sup.c is independently R, OR, CN, NO.sub.2, SR, S(O)R, SO.sub.2R, C(O)R, CO.sub.2R, C(O)N(R).sub.2, NRC(O)R, NRC(O)N(R).sub.2, NRSO.sub.2R, N(R).sub.2, or wherein R.sup.c is a 3-8 membered saturated, partially unsaturated, or aryl monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein R.sup. is optionally substituted with p occurrences of R.sup.d, wherein: p is 0 to 5; each R.sup.d is independently R, OR, CN, C(R).sub.3, NO.sub.2, SR, S(O)R, SO.sub.2R, C(O)R, CO.sub.2R, C(O)N(R).sub.2, NRC(O)R, NRC(O)N(R).sub.2, NRSO.sub.2R, or N(R).sub.2.

(120) In some embodiments, R.sup.4 is hydrogen, halogen or C.sub.1-6 aliphatic.

(121) In some embodiments, R.sup.4 is hydrogen, halogen or C.sub.1-6 aliphatic.

(122) In some embodiments, R.sup.4 and R.sup.4 are taken together to form an alkenylene substituted with one R.sup.c group, depicted herein as

(123) ##STR00034##
In some embodiments, R.sup.4 and R.sup.4 are taken together to form an alkenylene substituted with two R.sup.c groups, depicted herein as

(124) ##STR00035##

(125) In some embodiments, each R.sup.c is independently R, OR, CN, SR, S(O)R, SO.sub.2R, C(O)R, CO.sub.2R, or N(R).sub.2. In some embodiments, each R.sup.c is independently R. In some embodiments, each R.sup.c is independently OR, SR, or N(R).sub.2.

(126) In some embodiments, R.sup.c is a 3-8 membered saturated monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 3-8 membered saturated monocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 3-8 membered saturated monocyclic carbocycle, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 5-6 membered saturated monocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 5-6 membered saturated monocyclic carbocycle, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d.

(127) In some embodiments, R.sup.c is a 3-8 membered partially unsaturated monocyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 3-8 membered partially unsaturated monocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 3-8 membered partially unsaturated monocyclic carbocycle, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 5-6 membered partially unsaturated monocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 5-6 membered partially unsaturated monocyclic carbocycle, wherein R is optionally substituted with p occurrences of R.sup.d.

(128) In some embodiments, R.sup.c is a 5-6 membered aryl ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 5 membered aryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 6 membered aryl ring containing 1-4 nitrogens, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is phenyl optionally substituted with p occurrences of R.sup.d.

(129) In some embodiments, R.sup.c is an 8-10 membered saturated bicyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is an 8-10 membered saturated bicyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is an 8-10 membered saturated bicyclic carbocycle, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d.

(130) In some embodiments, R.sup.c is an 8-10 membered partially unsaturated bicyclic ring optionally containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is an 8-10 membered partially unsaturated bicyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is an 8-10 membered partially unsaturated bicyclic carbocycle, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d.

(131) In some embodiments, R.sup.c is a 9-10 membered bicyclic aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 9-10 membered bicyclic aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 9 membered bicyclic aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is a 10 membered bicyclic aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d. In some embodiments, R.sup.c is optionally substituted naphthyl, wherein R.sup.c is optionally substituted with p occurrences of R.sup.d.

(132) In some embodiments, R.sup.4 and R.sup.4 taken together form the following formula:

(133) ##STR00036##
wherein R.sup.d and p are as defined above and described herein.

(134) In some embodiments, R.sup.4 and R.sup.4 taken together form the following formula:

(135) ##STR00037##

(136) In some embodiments, R.sup.4 and R.sup.4 taken together form the following formula:

(137) ##STR00038##
wherein R.sup.d and p are as defined above and described herein.

(138) In some embodiments, R.sup.4 and R.sup.4 taken together form the following formula:

(139) ##STR00039##

(140) In some embodiments, the present invention provides a compound of either of the following formulae:

(141) ##STR00040##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.3, R.sup.4, R.sup.4, T.sup.1, and T.sup.2 are as defined and described herein.

(142) In some embodiments, the present invention provides a compound of either of the following formulae:

(143) ##STR00041##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.3, R.sup.4, R.sup.4, T.sup.1, and T.sup.2 are as defined and described herein.

(144) In some embodiments, the present invention provides a compound of either of the following formulae:

(145) ##STR00042##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.3, R.sup.4, R.sup.4, T.sup.1, and T.sup.2 are as defined and described herein.

(146) In some embodiments, the present invention provides a compound of either of the following formulae:

(147) ##STR00043##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.3, R.sup.4, R.sup.4, T.sup.1, and T.sup.2 are as defined and described herein. It would be apparent to one of skill in the art that all possible stereoisomers of the provided compounds are contemplated herein.

(148) In some embodiments, the present invention provides a compound of the formula:

(149) ##STR00044##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.4, T.sup.1, T.sup.2, L, Ring A, R.sup.a, and m are as defined and described herein.

(150) In some embodiments, the present invention provides a compound of the formula:

(151) ##STR00045##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.4, L, Ring A, R.sup.a, and m are as defined and described herein.

(152) In some embodiments, the present invention provides a compound of the formula:

(153) ##STR00046##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.c, L, Ring A, R.sup.a, and m are as defined and described herein.

(154) In some embodiments, the present invention provides a compound of the formula:

(155) ##STR00047##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.d, p, L, Ring A, R.sup.a, and m are as defined and described herein.

(156) In some embodiments, the present invention provides a compound of the formula:

(157) ##STR00048##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.d, p, L, Ring A, R.sup.a, and m are as defined and described herein.

(158) In some embodiments, the present invention provides a compound of either of the formulae:

(159) ##STR00049##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.4L, Ring A, R.sup.a, and m are as defined and described herein.

(160) In some embodiments, the present invention provides a compound of either of the formulae:

(161) ##STR00050##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, L, Ring A, R.sup.a, and m are as defined and described herein.

(162) In some embodiments, the provided compound is of one of the formulae:

(163) ##STR00051##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.3, L, Ring A, R.sup.a, and m are as defined and described herein.

(164) In some embodiments, the provided compound is of one of the formulae:

(165) ##STR00052##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, L, Ring A, R.sup.a, and m are as defined above.

(166) In some embodiments, the provided compound is of the formula:

(167) ##STR00053##
or a pharmaceutically acceptable salt thereof, wherein L, Ring A, R.sup.a, and m are as defined and described herein.

(168) In some embodiments, the provided compound is of the formula:

(169) ##STR00054##
or a pharmaceutically acceptable salt thereof, wherein L, Ring A, R.sup.a, and m are as defined and described herein.

(170) In some embodiments, the provided compound is of the formula:

(171) ##STR00055##
or a pharmaceutically acceptable salt thereof, wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.a, Ring A, and m are as defined above and herein.

(172) In some embodiments, the provided compound is of the formula:

(173) ##STR00056##
or a pharmaceutically acceptable salt thereof, wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.a, Ring A, and m are as defined above and herein.

(174) In some embodiments, the provided compound is of the formula:

(175) ##STR00057##
or a pharmaceutically acceptable salt thereof, wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.a, Ring A, and m are as defined above and herein.

(176) In some embodiments, the provided compound is of the formula:

(177) ##STR00058##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.a, Ring A, and m are as defined above and herein.

(178) In some embodiments, the provided compound is of one of the formulae:

(179) ##STR00059##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.a, Ring A, and m are as defined above and herein.

(180) In some embodiments, the provided compound is of one of the formulae:

(181) ##STR00060##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.a, Ring A, and m are as defined above and herein.

(182) In some embodiments, the provided compound is of the formula:

(183) ##STR00061##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.a, R.sup.b, Ring A, and m are as defined above and herein.

(184) In some embodiments, the provided compound is of the formula:

(185) ##STR00062##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.a, Ring A, and m are as defined above and herein.

(186) In some embodiments, the provided compound is of the formula:

(187) ##STR00063##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.a, Ring A, and m are as defined above and herein.

(188) In some embodiments, the provided compound is of the formula:

(189) ##STR00064##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.a, Ring A, and m are as defined above and herein.

(190) In some embodiments, the provided compound is of the formula:

(191) ##STR00065##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, Ring A, and m are as defined above and herein.

(192) In some embodiments, the provided compound is of the formula:

(193) ##STR00066##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, Ring A, and m are as defined above and herein.

(194) In some embodiments, the provided compound is of the formula:

(195) ##STR00067##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, Ring A, and m are as defined above and herein.

(196) In some embodiments, the provided compound is of the formula:

(197) ##STR00068##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, Ring A, and m are as defined above and herein.

(198) In some embodiments, the provided compound is of the formula:

(199) ##STR00069##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, L, R.sup.a, and m are as defined and described herein.

(200) In some embodiments, the provided compound is of the formula:

(201) ##STR00070##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.4, L, and m are as defined and described herein. In certain embodiments, a provided compound is as depicted above, wherein R.sup.4 and R.sup.4 are taken together to form

(202) ##STR00071##
In certain embodiments, a provided compound is as depicted above, wherein R.sup.4 and R.sup.4 are taken together to form

(203) ##STR00072##

(204) In some embodiments, the provided compound is of the formula:

(205) ##STR00073##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, L, R.sup.a, and m are as defined and described herein.

(206) In some embodiments, the provided compound is of the formula:

(207) ##STR00074##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.4, L, and m are as defined and described herein. In certain embodiments, a provided compound is as depicted above, wherein R.sup.4 and R.sup.4 are taken together to form

(208) ##STR00075##
In certain embodiments, a provided compound is as depicted above, wherein R.sup.4 and R.sup.4 are taken together to form

(209) ##STR00076##

(210) In some embodiments, the provided compound is of the formula:

(211) ##STR00077##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, L, and m are as defined and described herein.

(212) In some embodiments, the provided compound is of the formula:

(213) ##STR00078##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a and m are as defined and described herein.

(214) In some embodiments, the provided compound is of the formula:

(215) ##STR00079##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3 and R.sup.a are as defined and described herein.

(216) In some embodiments, the provided compound is of the formula:

(217) ##STR00080##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined and described herein.

(218) In some embodiments, the provided compound is of the formula:

(219) ##STR00081##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a and m are as defined and described herein.

(220) In some embodiments, the provided compound is of one of the formulae:

(221) ##STR00082##
or a pharmaceutically acceptable salt thereof, R.sup.a and m are as defined and described herein.

(222) In some embodiments, the provided compound is of one of the formulae:

(223) ##STR00083##
or a pharmaceutically acceptable salt thereof, R.sup.a and m are as defined and described herein.

(224) In some embodiments, the provided compound is of one of the formulae:

(225) ##STR00084##
or a pharmaceutically acceptable salt thereof, R.sup.a and m are as defined and described herein.

(226) In some embodiments, the provided compound is of the formula I-c:

(227) ##STR00085##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.a, R.sup.b, Ring A, Ring B, m, n, and Q are as defined above and herein.

(228) In some embodiments, the provided compound is of the formula:

(229) ##STR00086##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.a, R.sup.b, Ring A, Ring B, m, n, and Q are as defined above and herein.

(230) In some embodiments, the provided compound is of the formula:

(231) ##STR00087##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, Ring B, m, n, and Q are as defined above and herein.

(232) In some embodiments, the provided compound is of the formula:

(233) ##STR00088##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, Ring B, m, n, and Q are as defined above and herein.

(234) In some embodiments, the provided compound is of the formula:

(235) ##STR00089##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, Ring B, m, and n are as defined above and herein.

(236) In some embodiments, the provided compound is of the formula:

(237) ##STR00090##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, Ring B, m, and n are as defined above and herein.

(238) In some embodiments, the provided compound is of any one of the formulae:

(239) ##STR00091##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, Ring B, m, and n are as defined above and herein.

(240) In some embodiments, the provided compound is of the formula:

(241) ##STR00092##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, Ring B, m, and n are as defined above and herein.

(242) In some embodiments, the provided compound is of the formula:

(243) ##STR00093##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, m, n, L, and Q are as defined above and herein.

(244) In some embodiments, the provided compound is of the formula:

(245) ##STR00094##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, m, n, L, and Q are as defined above and herein.

(246) In some embodiments, the provided compound is of one of the formulae:

(247) ##STR00095##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, m, n, L, and Q are as defined above and herein.

(248) In some embodiments, the provided compound is of one of the formulae:

(249) ##STR00096##
or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.a, R.sup.b, Ring A, m, n, L, and Q are as defined above and herein.

(250) In some embodiments, the provided compound is of any of the formulae:

(251) ##STR00097##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a is as defined above and herein.

(252) In some embodiments, the provided compound is of any of the formulae:

(253) ##STR00098##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a is as defined above and herein.

(254) In some embodiments, the provided compound is of any of the formulae:

(255) ##STR00099##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a is as defined above and herein.

(256) In some embodiments, the provided compound is of any of the formulae:

(257) ##STR00100##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a is as defined above and herein.

(258) In some embodiments, the provided compound is of the formula:

(259) ##STR00101##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a is as defined above and herein.

(260) In some embodiments, the provided compound is of any of the formulae:

(261) ##STR00102##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, Ring B, m, n, and Q are as defined and described herein.

(262) In some embodiments, the provided compound is of any of the formulae:

(263) ##STR00103##
or a pharmaceutically acceptable salt thereof, wherein R.sup.b, Ring B, m, and Q are as defined and described herein.

(264) In some embodiments, the provided compound is of the formula:

(265) ##STR00104##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, Ring B, n, and Q are as defined and described herein.

(266) In some embodiments, the provided compound is of the formula:

(267) ##STR00105##
or a pharmaceutically acceptable salt thereof, wherein Ring B, R.sup.b, n, and Q are as defined and described herein.

(268) In some embodiments, the provided compound is of any of the formulae:

(269) ##STR00106##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, Ring B, and n are as defined and described herein.

(270) In some embodiments, the provided compound is of any of the formulae:

(271) ##STR00107##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, Ring B, and n are as defined and described herein.

(272) In some embodiments, the provided compound is of any of the formulae:

(273) ##STR00108##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, Ring B, m, and n are as defined and described herein.

(274) In some embodiments, the provided compound is of any of the formulae:

(275) ##STR00109##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, Ring B, m, and n are as defined and described herein.

(276) In some embodiments, the provided compound is of any of the formulae:

(277) ##STR00110##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, Ring B, m, and n are as defined and described herein.

(278) In some embodiments, the provided compound is of any of the formulae:

(279) ##STR00111##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, m, and n are as defined and described herein.

(280) In some embodiments, the provided compound is of any of the formulae:

(281) ##STR00112##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, m, and n are as defined and described herein.

(282) In some embodiments, the provided compound is of any of the formulae:

(283) ##STR00113##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, m, and n are as defined and described herein. In certain embodiments wherein the provided compound is as described and defined above, at least one R.sup.b is C(O)OtBu.

(284) In some embodiments, the provided compound is of any of the formulae:

(285) ##STR00114##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, Ring B, m, and n are as defined and described herein.

(286) In some embodiments, the provided compound is of the formula:

(287) ##STR00115##
or a pharmaceutically acceptable salt thereof, wherein R.sup.a, R.sup.b, and n are as defined and described herein.

(288) In certain embodiments, a compound of formula I is of any of the structures shown in Table 1 below:

(289) TABLE-US-00001 TABLE 1 0 0 0 0 0 0 0 0 00 01 02 03 04 05 06 07 08

(290) In some embodiments, total size of the compound does not exceed about 500 g/mol.

(291) In some embodiments, a CHD compound for use in accordance with the present invention has the structure:

(292) ##STR00209##
or a pharmaceutically acceptable salt thereof.

(293) In some embodiments, a CHD compound for use in accordance with the present invention has the structure:

(294) ##STR00210##
or a pharmaceutically acceptable salt thereof, wherein R is as defined and described herein.

(295) In some embodiments, a CHD compound for use in accordance with the present invention has the structure:

(296) ##STR00211##
or a pharmaceutically acceptable salt thereof; wherein R is as defined and described herein.

(297) In some embodiments, a provided compound is of Formula I, which compound is characterized by an ability to inhibit or reverse abnormal protein aggregation in vivo or in vitro. In some embodiments, a provided compound is of Formula I, which compound is characterized by an ability to protect cells from the cytotoxic effects of aggregated protein in vivo or in vitro. In some embodiments, a provided compound is of Formula I, which compound is characterized by an ability modulate proteasome activity in vivo or in vitro.

(298) In some embodiments, a CHD compound according to the present invention shows a maximum tolerated dose (e.g., when tested in a model organism such as a mouse) of at least about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 mg/kg IP. In some embodiments, a CHD compound according to the present invention shows a maximum tolerated dose of greater than about 150 mg/kg IP. In certain embodiments, a CHD compound according to the present invention shows a maximum tolerated dose of at least about 100 mg/kg IP.

(299) In some embodiments, a CHD compound according to the present invention has a therapeutic index of at least about five. In some embodiments, a CHD compound according to the present invention has a therapeutic index of about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, a CHD compound according to the present invention has a therapeutic index of about 25, 30, 35, 40, 45, or 50. In certain embodiments, a CHD compound according to the present invention has a therapeutic index of about ten.

(300) In some embodiments, a CHD compound according to the present invention is characterized by excellent oral availability. In some embodiments, a CHD compound according to the present invention shows about 70%, 80, or 90% oral availability. In some embodiments, a CHD compound according to the present invention shows about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% oral availability. In certain embodiments, a CHD compound according to the present invention shows about 100% oral availability.

(301) In some embodiments, a CHD compound according to the present invention is characterized by a metabolic half life of about 24 h. In some embodiments, a CHD compound according to the present invention is characterized by a metabolic half life of less than about 24 h. In some embodiments, a CHD compound according to the present invention is characterized by a metabolic half life of about 12 h. In some embodiments, a CHD compound according to the present invention is characterized by a metabolic half life of about 10 h. In some embodiments, a CHD compound according to the present invention is characterized by a metabolic half life of about 8 h. In some embodiments, a CHD compound according to the present invention is characterized by a metabolic half life of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 h. In some embodiments, a CHD compound according to the present invention is characterized by a metabolic half life of about 20, 30, 40, 50, 60, 70, 80, 90, or 100 minutes. In some embodiments, a CHD compound according to the present invention is characterized by a metabolic half life of at least about 45 minutes.

(302) In some embodiments, a CHD compound according to the present invention shows good blood brain barrier penetration in that a blood:brain concentration ratio of at least about 10:1 is observed. In some embodiments, a CHD compound according to the present invention shows a blood brain barrier penetration in that a blood:brain concentration ratio of about 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, or 1:1 is observed. In certain embodiments, a blood:brain concentration ratio of about 3:1 is observed.

(303) In some embodiments, a CHD compound according to the present invention is characterized by good tissue penetration such that intraperitoneal administration of 50 mg/kg achieves blood concentrations in the range of about 100, 125, 150, 175 or 200 M, and/or brain concentrations in the range of 30, 40, 50, 60, or 70 M (e.g., in a model organism such as a mouse). In some embodiments, intraperitoneal administration of about 60 mg/kg achieves a blood concentration of about 150 micromolar, and/or a brain concentration of about 50 micromolar. In some embodiments, intraperitoneal administration of about 50 mg/kg achieves a blood concentration of about 150 micromolar, and/or a brain concentration of about 50 micromolar. In some embodiments, intraperitoneal administration of about 40 mg/kg achieves a blood concentration of about 150 micromolar, and a brain concentration of about 50 micromolar. In some embodiments, intraperitoneal administration of less than about 40 mg/kg achieves a blood concentration of about 150 micromolar, and/or a brain concentration of about 50 micromolar. In some embodiments, intraperitoneal administration of about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg/kg achieves a blood concentration of about 150 micromolar, and/or a brain concentration of about 50 micromolar.

(304) In some embodiments, a CHD compound according to the present invention is characterized by good tissue penetration such that oral administration of 50 mg/kg achieves blood concentrations in the range of about 100, 125, 150, 175 or 200 micromolar, and/or brain concentrations in the range of 30, 40, 50, 60, or 70 micromolar (e.g., in a model organism such as a mouse). In some embodiments, oral administration of about 60 mg/kg achieves a blood concentration of about 150 micromolar, and/or a brain concentration of about 50 micromolar. In some embodiments, oral administration of about 50 mg/kg achieves a blood concentration of about 150 micromolar, and/or a brain concentration of about 50 micromolar. In some embodiments, oral administration of about 40 mg/kg achieves a blood concentration of about 150 micromolar, and a brain concentration of about 50 micromolar. In some embodiments, oral administration of less than about 40 mg/kg achieves a blood concentration of about 150 micromolar, and/or a brain concentration of about 50 micromolar. In some embodiments, oral administration of about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg/kg achieves a blood concentration of about 150 micromolar, and/or a brain concentration of about 50 micromolar.

(305) In some embodiments, a CHD compound according to the present invention exhibits EC.sub.50 values of less than about 30 M. In some embodiments, a CHD compound according to the present invention exhibits EC.sub.50 values of less than about 20 M. In some embodiments, a CHD compound according to the present invention exhibits EC.sub.50 values of less than about 10 In some embodiments, a CHD compound according to the present invention exhibits EC.sub.50 values of about 9, 8, 7, 6, 5, 4, 3, 2, or 1 M. In certain embodiments, a CHD compound according to the present invention exhibits EC.sub.50 values of less than about 1 M. In certain embodiments, a CHD compound according to the present invention exhibits EC.sub.50 values between 0.5 and 5.0 M. In certain embodiments, a CHD compound according to the present invention exhibits an EC.sub.50 value of about 2 M.

(306) Neurodegenerative Diseases Treated in Accordance with the Present Invention

(307) Imbalances in protein homeostasis are often associated with protein misfolding and/or protein conformational changes that lead to protein aggregation and formation of protein inclusion bodies. Many neurodegenerative diseases, including the polyglutamine (polyQ)-repeat diseases, Alzheimer's disease, Parkinson's disease, prion diseases, frontotemporal lobar degeneration, and ALS, are characterized by the appearance of damaged and aggregated proteins, including huntingtin, polyQ proteins, amyloid A prion (PrP and Sup35) fibrils, and mutant SOD1 (Taylor et al., Science. 2002, 296(5575), 1991-5; Ross, C. A., Neuron. 1997, 19(6), 1147-50; Perutz, M. F., Brain Res Bull. 1999, 50(5-6), 467; and Kopito et al., Nat Cell Bio. 2000, 2(11), E207-9). The fact that such diverse proteins form aggregates in patients with distinct neurological diseases suggests that a common molecular etiology may contribute to the neuropathology in these diseases and that, perhaps, protein misfolding and the subsequent appearance of protein aggregates are early events that play a role in neuronal toxicity in multiple human neurological diseases (On, H. T., Genes Dev. 2001, 15(8), 925-32; Ikeda et al., Nat Genet. 1996, 13(2), 196-202; DiFiglia et al., Science. 1997, 277(5334), 1990-3; Davies et al., Cell. 1997, 90(3), 537-48; Koo et al., Proc Nall Acad Sci USA. 1999, 96(18), 9989-90).

(308) One model for the molecular basis of these neurodegenerative diseases is that insoluble protein aggregates associate and interfere with the activity of other critical soluble cellular proteins, and that loss of function of these diverse proteins has serious negative consequences on cellular function. The affected proteins may include ubiquitin, components of the proteasome, components of the cytoskeleton, transcription factors (TBP (TATA binding protein), EYA (Eyes Absent protein), CBP (CREB binding protein), and molecular chaperones Hsc-70, Hsp-70, Hdj-1, and Hdj-2 (Davies et al., Cell. 1997, 90(3), 537-48; Ross, C. A., Neuron. 2002, 35(5), 819-22; Cummings et al., Nat Genet. 1998, 19(2) 148-54; Perez et at., J Cell Biol. 1998, 143(6), 1457-70; Kazantsev et al., Proc Nall Acad Sci USA. 1999, 96(20), 11404-9; Jana et al., Hum Mol Genet. 2001, 10(10), 1049-59; Nucifora et al., Science. 2001, 291(5512) 2423-8; and Suhr et al., J Cell Biol. 2001, 153(2), 283-94). Recent studies showed that TBP and CBP are irreversibly sequestered in polyQ/huntington aggregates, while the chaperone Hsp70 is transiently associated with the surface (Chai et al., Proc Natl Acad Sci USA. 2002, 99(14), 9310-5; Kim et al., Nat Cell Biol. 2002, 4(10), 826-31). Sequestration of CBP into polyglutamine aggregates is linked directly with loss of cellular function in neuronal cells, and overexpression of CBP suppressed polyQ toxicity (Nucifora et al., Science. 2001, 291(5512) 2423-8). Furthermore, expression of polyglutamine proteins in C. elegans causes other metastable proteins to lose function. Thus, a single aggregation-prone protein may be able to destabilize protein homeostasis in otherwise normal cells (Gidalevitz et at., Science 2006, 311(5766) 1471-1474). These studies indicate that the sequestration of essential soluble cellular proteins in insoluble protein aggregates could play a significant role in the neuropathology and neurotoxicity in ALS and related diseases.

(309) It is also possible that the cellular mechanism(s) that remove misfolded or damaged proteins (Morimoto, R. I., Cell. 2002, 110(3), 281-4; Horwich et al., Cell. 1997, 89(4), 499-510; and Nollen et al., J Cell Sci. 2002, 115(Pt 14) 2809-16) are overwhelmed in neurodegenerative diseases due to the presence of abundant protein aggregates. The activity of molecular chaperones is one of the most important mechanisms to prevent and/or rescue protein misfolding and aggregation. Molecular chaperones are a large and diverse protein family which includes Hsp104, Hsp90, Hsp70, dnaJ (Hsp40), immunophilins (Cyp40, FKBP), Hsp60 (chaperonins), the small heat shock proteins, and components of the steroid aporeceptor complex (p23, Hip, Hop, Bag1) (Gething, M. J., Nature. 1997, 388(6640) 329, 331; Bakau, b., Amsterdam: Harwood Academic Publishers. 1999, 690). Molecular chaperones ensure proper protein folding by preventing hydrophobic surfaces from interacting with each other, by enhancing protein refolding, and when necessary, by stimulating protein degradation to remove misfolded proteins that tend to aggregate (Horwich et al., Cell. 1997, 89(4), 499-510; Bakau, b., Amsterdam: Harwood Academic Publishers. 1999, 690; Schroder et al., Embo J. 1993, 12(11), 4137-44; Parsell et al., Nature 1994, 372(6505), 475-8; Hartl, F. U., Nature. 1996, 381(6583) 571-9; and Morimoto et al., Nat. Biotechnol. 1998, 16(9), 833-8). Accordingly, overexpression of molecular chaperones can suppress the toxicity of mutant huntingtin, -synuclein, and SOD1 (Sakahira at al., Proc. Natl. Acad. Sci. USA. 2002, 99 Suppl. 4, 6412-8; Stenoien et al., Hum. Mol. Genet. 1999, 8(5), 731-41; Warrick et al., Nat. Genet. 1999, 23(4), 425-8; Carmichael et al., Proc. Natl. Acad. Sci. USA. 2000, 97(17), 9701-5; Takeuchi et at., Brain Res. 2002, 949(1-2), 11-22; Auluck et al., Science 2002, 295(5556), 865-8; and Bailey et at., Hum. Mol Genet. 2002, 11(5), 515-23). Recently, non-chaperone proteins were identified that also suppress toxicity associated with protein aggregation (Kazemi-Esfarjani et al., Science 2000, 287(5459), 1837-40; and Kazemi-Esfarjani et al., Hum. Mol. Genet. 2002, 11(21), 2657-72).

(310) The chaperone system is a highly appealing therapeutic target, because multiple small molecular weight modulators of chaperone activity have already been identified, two of which are active in a mouse model of ALS (Westerheide et al., J. Biol. Chem. 2005, 280(39), 33097-100; Kieran et at., Nat. Med. 2004, 10(4), 402-5; and Traynor et al., Neurology. 2006, 67(1), 20-7). Accordingly, recent analyses identified protein folding/misfolding and protein aggregation as a relevant therapeutic target for neurodegenerative diseases (Pasinelli et el., Nat. Rev. Neurosci. 2006, 7(9), 710-23; Lansbury et al., Nature. 2006, 443(7113), 774-9; Rubinsztein et al., Nature 2006, 443(7113), 780-6).

(311) Methods of Using CHD Compounds in Accordance with the Present Invention

(312) The present invention encompasses the recognition that provided CHD compounds can be effective in treating patients with amyotrophic lateral sclerosis (ALS) or other neurodegenerative diseases characterized by the presence of aberrant protein aggregates. Without wishing to be bound by any particular theory or mechanism of action, methods of the invention are useful in inhibiting or reversing abnormal protein aggregation or reducing the toxicity of protein aggregation (e.g., SOD1 or TDP-43). The invention provides methods for treating a subject suffering from or susceptible to ALS or other neurodegenerative disease including the step of administering to the subject a therapeutically effective amount of a provided CHD compound or a pharmaceutical composition thereof. In certain embodiments, the subject is a transgenic mouse. In certain embodiments, the subject is an adult human. In certain embodiments, the ALS being treated is familial ALS. In certain embodiments, the ALS being treated is sporadic ALS.

(313) In some embodiments, the neurodegenerative disease characterized by the presence of aberrant protein aggregates is Parkinson's disease (PD), diffuse Lewy body disease (DLBD), multiple system atrophy (MSA), and pantothenate kinase-associated neurodegeneration (PANK), Huntington's Disease (HD), prion diseases (e.g., Creutzfeldt Jakob disease), Alzheimer's Disease (AD), or frontotemporal lobar degeneration (FTLD).

(314) In some embodiments, the invention provides a method comprising steps of administering to a subject suffering from or susceptible to ALS an effective amount of a provided CHD compound, such that the severity or incidence of one or more symptoms of ALS is reduced, or its onset is delayed. In some embodiments, a provided CHD compound is administered in the form of a salt or pharmaceutically acceptable composition thereof. In certain embodiments, a provided CHD compound is administered in accordance with the present invention to subjects suffering from or susceptible to a neurodegenerative disease, disorder, or condition in a form or composition and/or according to a regimen useful in the treatment of ALS. In certain embodiments, the subject suffering from or susceptible to ALS is a human from about 40 to about 85 years of age.

(315) In some embodiments, the ALS being treated is characterized by the presence of abnormal protein aggregates such as, for example, SOD1 protein aggregates or TDP-43 protein aggregates. Exemplary such SOD1 protein aggregates include G93A SOD1 and G85R SOD1 protein aggregates. Without wishing to be bound by any particular theory, use of provided CHD compound in the treatment of ALS may reduce or delay the formation of such protein aggregates.

(316) In some embodiments, a provided CHD compound is administered once a day. In some embodiments, a provided CHD compound is administered two, three, four, or five times a day. In some embodiments, a provided CHD compound is administered every other day. In some embodiments, a provided CHD compound is administered every two days. In some embodiments, a provided CHD compound is administered every three days. In some embodiments, a provided CHD compound is administered every four days. In some embodiments, a provided CHD compound is administered every five days. In some embodiments, a provided CHD compound is administered every six days. In some embodiments, a provided CHD compound is administered once a week. In some embodiments, a provided CHD compound is administered at intervals as instructed by a physician for the duration of the life of the subject being treated. In certain embodiments, a provided CHD compound is administered as many times a day as necessary to provide a therapeutically effective amount of a provided CHD compound to treat a subject suffering from or susceptible to ALS.

(317) In some embodiments, the subject suffering from or susceptible to ALS is a mammal. In some embodiments, the subject suffering from or susceptible to ALS is a rodent, such as a rat or mouse, for example, a mouse model of ALS. In certain embodiments, the subject suffering from or susceptible to ALS is a human. In certain embodiments, the human is about 20, 30, 40, 50, 60, 70, 80, 90, or 100 years of age. In certain embodiments, the human is between 40 and 85 years of age.

(318) The efficacy of a provided CHD compound in the treatment of neurodegenerative diseases according to the present invention may be evaluated and followed using any method known in the medical arts. The treatment of ALS may be evaluated, for example, by physical examination, laboratory testing, imaging studies, electrophysiological studies, etc. In some embodiments, the treatment of ALS may be evaluated by monitoring the subject being treated. In some embodiments, the subject is monitored by monitoring motor function. In some embodiments, the subject is monitored by monitoring body weight. In some embodiments, the subject is monitored by monitoring survival time. In some embodiments, the subject is monitored one, two, three, four, or five times a day. In some embodiments, the subject is monitored one, two, three, four or five times a week. In some embodiments, the subject is monitored twice a week. In some embodiments, monitoring is continuous. In some embodiments, monitoring occurs for the duration of the subject's life. In certain embodiments, the subject is monitored one, two, or three times a day by monitoring body weight. In some embodiments, the subject is a human and is monitored using any of the methods known in the medical arts suitable for monitoring humans suffering from or susceptible to a neurodegenerative disease such as ALS. Exemplary such methods of monitoring include monitoring neurological function, respiratory function (e.g., pulmonary function test), muscle strength, speech, swallowing function, etc. In some embodiments, monitoring may comprise checking for signs of toxicity; in certain embodiments, toxicity is measured using any of the methods previously developed to measure toxicity of a provided CHD compound in patients being treated for schizophrenia.

(319) Dosages of a provided CHD compound utilized in accordance with the present invention may vary with the form of administration and/or with the particular subject being treated for ALS. In general, a provided CHD compound is most desirably administered at a concentration level that will afford effective results without causing any harmful or deleterious side-effects. In some embodiments, a provided CHD compound is administered in doses ranging from about 0.5 to about 500 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 5 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 10 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 20 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 30 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 40 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 50 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 60 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 70 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 80 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 90 to about 100 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses of less than about 20 mg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 1 mg/kg/day to about 50 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 1 mg/kg/day to about 40 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 1 mg/kg to about 30 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 1 mg/kg/day to about 20 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 1 mg/kg/day to about 10 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 10 mg/kg/day to about 50 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 10 mg/kg/day to about 40 mg/k/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 10 mg/kg/day to about 30 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 10 mg/kg/day to about 20 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 20 mg/kg/day to about 50 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 20 mg/kg/day to about 40 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 20 mg/kg/day to about 30 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging about 25 mg/kg/day to about 50 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging about 30 mg/kg/day to about 50 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 30 mg/kg/day to about 40 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 40 mg/kg/day to about 50 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses less than about 10 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses less than about 5 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses less than about 2 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses less than about 1 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses less than about 0.1 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses less than about 0.01 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses less than about 0.001 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses of about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, or 0.09 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 0.1 mg/kg/day to about 1 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 0.01 mg/kg/day to about 0.1 mg/kg/day. In some embodiments, a provided CHD compound is administered in doses ranging from about 0.001 mg/kg/day to about 0.01 mg/kg/day.

(320) In some embodiments, a provided CHD compound is administered systemically in any one of the doses described herein and suitable for the treatment of ALS. Systemic administration may comprise enteral or parenteral administration. In certain embodiments, systemic administration comprises oral administration in solid or solution form in any one of the doses described herein. In certain embodiments, a provided CHD compound is administered parenterally in any one of the doses described herein. In certain embodiments, a provided CHD compound is administered intraperitoneally in any one of the doses described herein and the subject is a mouse or rat with ALS. In some embodiments, a provided CHD compound is administered orally and the subject is a human with ALS.

(321) In some embodiments, the invention provides a method comprising steps of administering to a subject suffering from or susceptible to abnormal protein aggregation an amount of a provided CHD compound sufficient to reduce or delay such abnormal protein aggregation. In certain embodiments, reduction or inhibition of abnormal protein aggregation occurs in vivo in a subject with ALS or another neurodegenerative disease characterized by aberrant protein aggregation (e.g., Huntington's disease, prion disease, or Alzheimer's disease). In some embodiments, the subject is a mammal. In some embodiments, the subject is a mouse or rat. In some embodiments, the subject is a human. In certain embodiments, the human is about 20, 30, 40, 50, 60, 70, 80, 90, or 100 years of age. In some embodiments, abnormal protein aggregation comprises SOD1 protein aggregates. In certain embodiments, abnormal protein aggregation comprises G93A SOD1 protein aggregates. In certain embodiments, abnormal protein aggregation comprises G85R SOD1 protein aggregates. In certain embodiments, abnormal protein aggregation comprises TDP-43 protein aggregates.

(322) In some embodiments, the invention provides a method comprising the steps of administering to a cell in vitro an amount of a provided CHD compound effective to inhibit or reverse the toxic effect of abnormal protein aggregation. In certain embodiments, contact occurs in vitro, and the cell is derived from a mammalian cell line. In certain embodiments, contact occurs in vitro, and the cell is derived from a PC12 cell line. In certain embodiments, PC12 cells may additionally contain a detectable moiety to measure the extent of inhibition of aggregation. In certain embodiments, a detectable moiety is associated with a protein (e.g., a type of SOD1 protein, such as G93A SOD1 and/or G85R SOD1, or a type of TDP-43 protein). In certain embodiments, the detectable moiety is a fluorescent moiety (e.g., a YFP tag). In some embodiments, the detectable moiety is a phosphorescent moiety, a radiolabel, or any other detectable moiety known in the art, and may be detected using any of the methods known in the art. In some embodiments, the detectable moiety may be detected using a high content microscopy system to allow for high-throughput screening. In certain embodiments, the detectable moiety allows for the measurement of cell viability.

(323) In some embodiments, the invention provides a method comprising the steps of administering to a cell in vitro an amount of a provided CHD compound effective to protect against aggregated SOD1. In certain embodiments, protection occurs in vitro in a cell culture. In some embodiments, compounds of the invention are contacted with a cell line in vitro and the cell line is a mammalian cell line. In certain embodiments, the cell line is the PC12 cell line. In some embodiments, cells are associate with a detectable moiety such as those described above. In some embodiments, cells contain a protein labeled with a detectable moiety. In certain embodiments, the protein is SOD1 (e.g., G93A SOD1 and/or G85R SOD1) and the detectable moiety is a fluorescent moiety. In certain embodiments, the detectable moiety is a fluorescent moiety (e.g., a YFP tag) that may be detected using a high content microscopy system to allow for high-throughput screening. In some embodiments, the detectable moiety is a phosphorescent moiety, an epitope, radiolabel, or any other detectable moiety known in the art, and may be detected using any of the methods known in the art. In certain embodiments, the detectable moiety allows for the measurement of cell viability.

(324) In some embodiments, the invention provides a method comprising the steps of administering to a cell in vitro an amount of a provided CHD compound effective to modulate proteasome function. In certain embodiments, the cell is derived from a mammalian cell line. In some embodiments, the cell is derived from a PC12 cell line or a HeLa cell line. In certain embodiments, the cells contain a detectable moiety to measure the extent to which proteasome activity is inhibited. In certain embodiments, the protein is SOD1 (e.g., G93A SOD1 and/or G85R SOD1) and the detectable moiety is a fluorescent moiety. In certain embodiments, the protein is TDP-43. In certain embodiments, the detectable moiety is a fluorescent moiety such as a Ubi-YFP tag. In some embodiments, the detectable moiety is a Ubi-YFP tag and is detectable by fluorescence microscopy. In some embodiments, the detectable moiety is a phosphorescent moiety, an epitope, a radiolabel, or any other detectable moiety known in the art, and may be detected using any of the methods known in the art. In some embodiments, the detectable moiety may be detected using a high content microscopy system to allow for high-throughput screening. In certain embodiments, cell viability is measured.

(325) In some embodiments, the present invention provides systems, methods, and/or reagents to characterize provided CHD compounds and compositions. In some embodiments, the present invention provides assays to identify forms of provided CHD compounds and compositions that protect against protein aggregate-induced cytotoxicity. In certain embodiments, the assays are cell protection assays. Cell protection assays may used to identify provided CHD compounds and compositions that protect cells from the cytotoxic effects of aberrant protein aggregation. In some embodiments, the assays are protein aggregation inhibition assays that are used to identify provided CHD compounds and compositions that inhibit protein aggregation in a cell or in vitro.

(326) In some embodiments, the present invention provides a method of identifying provided CHD compounds and compositions that protect against protein aggregate-induced cytotoxicity comprising contacting a cell expressing SOD1, TDP-43, or another protein susceptible to aggregation with a test compound, incubating the cell with the test compound under suitable conditions for an amount of time sufficient to observe a protective effect against protein aggregate-induced cytotoxicity, and then measuring viability in the cells treated with the test compound. In some embodiments, the extent of protein aggregation-induced cytotoxicity is measured by determining the level of a detectable moiety (e.g., a fluorescent moiety) in the cell.

(327) In certain embodiments, the expressed protein in the cell used in the assay is a mutant SOD1 protein. In certain embodiments, the expressed protein the cell used in the assay is a mutant TDP-43 protein. In some embodiments, the expressed protein is SOD1 protein associated with a detectable moiety. In certain embodiments, the expressed protein is a fluorescently tagged mutant SOD1 protein, and the fluorescent moiety is a YFP tag. In some embodiments, the detectable moiety is a phosphorescent moiety, epitope, or radiolabel. In some embodiments, the detectable moiety is any suitable detectable moiety known to those or ordinary skill in the art and may be detected using any method known in the art. In some embodiments, the detectable moiety is a fluorescent tag (e.g., a YFP tag) that can be detected with a high content microscopy system. In some embodiments, the high content microscopy system detects cell viability and facilitates high-throughput screening of a plurality of provided CHD compounds.

(328) Cells may be pre-treated with an agent that modulates the expression of a protein of interest (e.g., SOD1, TDP-43) in the assay. The agent may, for instance, induce the expression of a gene responsible for the protein of interest (e.g., doxycycline-inducible promoter). In some embodiments, cells may also be treated with an agent that modulates proteasome activity. In certain embodiments, the agent may be a proteasome inhibitor (e.g., MG132). In some embodiments, cell viability of cells pre-treated with an agent described herein is measured using methods described above.

(329) In certain embodiments, the time of incubation of a cell with a provided CHD compound or composition ranges from approximately 1 minute to approximately 1 week. In some embodiments, the time of incubation ranges from approximately 5 minutes to approximately 1 week. In some embodiments, the time of incubation ranges from approximately 30 minutes to approximately 2 days. In some embodiments, the time of incubation ranges from approximately 30 minutes to approximately 1 day. In some embodiments, the time of incubation ranges from approximately 1 hour to approximately 1 day. In some embodiments, the time of incubation ranges from approximately 1 hour to approximately 18 hours. In some embodiments, the time of incubation ranges from approximately 1 hour to approximately 12 hours. In some embodiments, the time of incubation ranges from approximately 1 hour to approximately 6 hours. In some embodiments, the time of incubation ranges from approximately 1 hour to approximately 3 hours. In some embodiments, the time of incubation is approximately 6 hours. In some embodiments, the time of incubation is approximately 12 hours. In some embodiments, the time of incubation is approximately 18 hours. In some embodiments, the time of incubation is approximately 24 hours.

(330) In certain embodiments, the temperature during incubation of a cell with a provided CHD compound or composition ranges from approximately 20 C. to approximately 45 C. In certain embodiments, the temperature ranges from approximately 20 C. to approximately 40 C. In certain embodiments, the temperature ranges from approximately 25 C. to approximately 40 C. In certain embodiments, the temperature ranges from approximately 30 C. to approximately 40 C. In certain embodiments, the temperature is approximately 30 C. In certain embodiments, the temperature is approximately 37 C.

(331) Provided CHD compounds or compositions that are active in the above-mentioned assay could theoretically protect against abnormal protein aggregate-induced cytotoxicity through a number of biological mechanisms. The present invention additionally provides methods to screen for provided CHD compounds or compositions that protect against abnormal protein-aggregate induced cytotoxicity wherein the protein aggregation is inhibited in a non-specific manner.

(332) Provided CHD compounds or compositions which inhibit aberrant protein aggregation can be identified using methods similar to those described above in the aforementioned cytotoxicity assay. In some embodiments, the present invention provides a method of identifying provided CHD compounds or compositions that inhibit aberrant protein aggregation comprising contacting a cell expressing SOD1 or other protein susceptible to aggregation with a provided CHD compound or composition, incubating the cell with the compound or composition under suitable conditions, and then measuring the extent of protein aggregation in the cells treated with the provided CHD compound or composition as compared to a control. In certain embodiments, the extent of inhibition of protein aggregation is measured by staining the protein aggregates with a detectable stain (e.g., Image-iT plasma membrane dye). In some embodiments, the detectable stain is detected using a scanning device (e.g., Cellomics Arrayscan). In certain embodiments, the protein aggregates are detected using any method of detecting protein aggregates known in the art.

(333) Provided CHD compounds and compositions identified using the above-mentioned assays may be further examined using biological assays to guide structure-activity relationship (SAR) analyses of the identified compounds. Biological assays and SAR analyses are known to those of skill in the art.

(334) Pharmaceutical Compositions

(335) In another aspect, the present invention provides pharmaceutically compositions, which comprise a therapeutically effective amount of one or more of the inventive compounds, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. As described in detail, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginally or intrarectally, for example, as a pessary, cream or foam; sublingually; ocularly; transdermally; or nasally, pulmonary and to other mucosal surfaces.

(336) The phrase pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

(337) The phrase pharmaceutically acceptable carrier as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be acceptable in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.

(338) As set out herein, certain embodiments of the present compounds may contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids. The term pharmaceutically acceptable salts in this respect refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed during subsequent purification. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laureate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. See, for example, Berge et al. (1977) Pharmaceutical Salts, J. Pharm. Sci. 66:1-19; incorporated herein by reference.

(339) The pharmaceutically acceptable salts of the subject compounds include the conventional nontoxic salts or quaternary ammonium salts of the compounds, e.g., from non-toxic organic or inorganic acids. For example, such conventional nontoxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.

(340) In other cases, compounds of the present invention may contain one or more acidic functional groups and, thus, may be capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable bases. The term pharmaceutically-acceptable salts in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically-acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. See, for example, Berge et al., supra.

(341) Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

(342) Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

(343) Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, and the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, this amount will range from about 1% to about 99% of active ingredient, preferably from about 5% to about 70%, most preferably from about 10% to about 30%.

(344) In certain embodiments, a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention. In certain embodiments, an aforementioned formulation renders orally bioavailable a compound of the present invention.

(345) Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

(346) Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.

(347) In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; absorbents, such as kaolin and bentonite clay; lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

(348) A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made in a suitable machine in which a mixture of the powdered compound is moistened with an inert liquid diluent.

(349) The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

(350) Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

(351) Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

(352) Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

(353) Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.

(354) Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

(355) The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

(356) Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyimide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

(357) Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Dissolving or dispersing the compound in the proper medium can make such dosage forms. Absorption enhancers can also be used to increase the flux of the compound across the skin. Either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel can control the rate of such flux.

(358) Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.

(359) Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

(360) Examples of suitable aqueous and nonaqueous carriers, which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

(361) These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

(362) In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

(363) Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions, which are compatible with body tissue.

(364) In certain embodiments, a compound or pharmaceutical preparation is administered orally. In other embodiments, the compound or pharmaceutical preparation is administered intravenously. Alternative routs of administration include sublingual, intramuscular, and transdermal administrations.

(365) When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1% to 99.5% (more preferably, 0.5% to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.

(366) Preparations of compounds described herein may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.

(367) The phrases parenteral administration and administered parenterally as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

(368) The phrases systemic administration, administered systemically, peripheral administration, and administered peripherally as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

(369) These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.

(370) Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.

(371) Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

(372) The selected dosage level may depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

(373) A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and then gradually increasing the dosage until the desired effect is achieved.

(374) In some embodiments, a compound or pharmaceutical composition of the invention is provided to a subject suffering from or susceptible to a neurodegenerative disease chronically. Chronic treatments include any form of repeated administration for an extended period of time, such as repeated administrations for one or more months, between a month and a year, one or more years, or longer. In many embodiments, a chronic treatment involves administering a compound or pharmaceutical composition of the invention repeatedly over the life of the subject. Preferred chronic treatments involve regular administrations, for example one or more times a day, one or more times a week, or one or more times a month. In general, a suitable dose such as a daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally doses of the compounds of this invention for a patient, when used for the indicated effects, will range from about 0.0001 to about 100 mg per kg of body weight per day. Preferably the daily dosage will range from 0.001 to 50 mg of compound per kg of body weight, and even more preferably from 0.01 to 20 mg of compound per kg of body weight. However, lower or higher doses can be used. In some embodiments, the dose administered to a subject may be modified as the physiology of the subject changes due to age, disease progression, weight, or other factors.

(375) If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six, or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.

(376) In some embodiments, a CHD compound as described herein may be administered neat. More commonly, however, it will be administered as part of a pharmaceutical formulation (composition) as described above.

(377) Compounds described herein may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other pharmaceuticals.

(378) According to the invention, compounds for treating neurodegenerative diseases, disorders, or conditions can be formulated or administered using methods that help the compounds cross the blood-brain barrier (BBB). The vertebrate brain (and CNS) has a unique capillary system unlike that in any other organ in the body. The unique capillary system has morphologic characteristics which make up the blood-brain barrier (BBB). The blood-brain barrier acts as a system-wide cellular membrane that separates the brain interstitial space from the blood.

(379) Unique morphologic characteristics of the brain capillaries that make up the BBB include: (a) epithelial-like high resistance tight junctions which literally cement all endothelia of brain capillaries together, and (b) scanty pinocytosis or transendothelial channels, which are abundant in endothelia of peripheral organs. Due to the unique characteristics of the blood-brain barrier, hydrophilic drugs and peptides that readily gain access to other tissues in the body are barred from entry into the brain or their rates of entry and/or accumulation in the brain are very low.

(380) In one aspect of the invention, compounds described herein that cross the BBB are particularly useful for treating neurodegenerative diseases. In one embodiment, compounds described herein that cross the BBB are particularly useful for treating amyotrophic lateral sclerosis (ALS). Therefore it will be appreciated by a person of ordinary skill in the art that some of the compounds of the invention might readily cross the BBB. Alternatively, the compounds of the invention can be modified, for example, by the addition of various substitutents that would make them less hydrophilic and allow them to more readily cross the BBB.

(381) Various strategies have been developed for introducing those drugs into the brain which otherwise would not cross the blood-brain barrier. Widely used strategies involve invasive procedures where the drug is delivered directly into the brain. One such procedure is the implantation of a catheter into the ventricular system to bypass the blood-brain barrier and deliver the drug directly to the brain. These procedures have been used in the treatment of brain diseases which have a predilection for the meninges, e.g., leukemic involvement of the brain (U.S. Pat. No. 4,902,505, incorporated herein in its entirety by reference).

(382) Although invasive procedures for the direct delivery of drugs to the brain ventricles have experienced some success, they are limited in that they may only distribute the drug to superficial areas of the brain tissues, and not to the structures deep within the brain. Further, the invasive procedures are potentially harmful to the patient.

(383) Other approaches to circumventing the blood-brain barrier utilize pharmacologic-based procedures involving drug latentiation or the conversion of hydrophilic drugs into lipid-soluble drugs. The majority of the latentiation approaches involve blocking the hydroxyl, carboxyl and primary amine groups on the drug to make it more lipid-soluble and therefore more easily able to cross the blood-brain barrier.

(384) Another approach to increasing the permeability of the BBB to drugs involves the intra-arterial infusion of hypertonic substances which transiently open the blood-brain barrier to allow passage of hydrophilic drugs. However, hypertonic substances are potentially toxic and may damage the blood-brain barrier.

(385) Antibodies are another method for delivery of compositions of the invention. For example, an antibody that is reactive with a transferrin receptor present on a brain capillary endothelial cell, can be conjugated to a neuropharmaceutical agent to produce an antibody-neuropharmaceutical agent conjugate (U.S. Pat. No. 5,004,697, incorporated herein in its entirety by reference). The method is conducted under conditions whereby the antibody binds to the transferrin receptor on the brain capillary endothelial cell and the neuropharmaceutical agent is transferred across the blood brain barrier in a pharmaceutically active form. The uptake or transport of antibodies into the brain can also be greatly increased by cationizing the antibodies to form cationized antibodies having an isoelectric point of between about 8.0 to 11.0 (U.S. Pat. No. 5,527,527, incorporated herein in its entirety by reference).

(386) A ligand-neuropharmaceutical agent fusion protein is another method useful for delivery of compositions to a host (U.S. Pat. No. 5,977,307, incorporated herein in its entirety by reference). The ligand is reactive with a brain capillary endothelial cell receptor. The method is conducted under conditions whereby the ligand binds to the receptor on a brain capillary endothelial cell and the neuropharmaceutical agent is transferred across the blood brain barrier in a pharmaceutically active form. In some embodiments, a ligand-neuropharmaceutical agent fusion protein, which has both ligand binding and neuropharmaceutical characteristics, can be produced as a contiguous protein by using genetic engineering techniques. Gene constructs can be prepared comprising DNA encoding the ligand fused to DNA encoding the protein, polypeptide or peptide to be delivered across the blood brain barrier. The ligand coding sequence and the agent coding sequence are inserted in the expression vectors in a suitable manner for proper expression of the desired fusion protein. The gene fusion is expressed as a contiguous protein molecule containing both a ligand portion and a neuropharmaceutical agent portion.

(387) The permeability of the blood brain barrier can be increased by administering a blood brain barrier agonist, for example bradykinin (U.S. Pat. No. 5,112,596, incorporated herein in its entirety by reference), or polypeptides called receptor mediated permeabilizers (RMP) (U.S. Pat. No. 5,268,164, incorporated herein in its entirety by reference). Exogenous molecules can be administered to the host's bloodstream parenterally by subcutaneous, intravenous or intramuscular injection or by absorption through a bodily tissue, such as the digestive tract, the respiratory system or the skin. The form in which the molecule is administered (e.g., capsule, tablet, solution, emulsion) depends, at least in part, on the route by which it is administered. The administration of the exogenous molecule to the host's bloodstream and the intravenous injection of the agonist of blood-brain barrier permeability can occur simultaneously or sequentially in time. For example, a therapeutic drug can be administered orally in tablet form while the intravenous administration of an agonist of blood-brain barrier permeability is given later (e.g., between 30 minutes later and several hours later). This allows time for the drug to be absorbed in the gastrointestinal tract and taken up by the bloodstream before the agonist is given to increase the permeability of the blood-brain barrier to the drug. On the other hand, an agonist of blood-brain barrier permeability (e.g., bradykinin) can be administered before or at the same time as an intravenous injection of a drug. Thus, the term co-administration is used herein to mean that the agonist of blood-brain barrier and the exogenous molecule will be administered at times that will achieve significant concentrations in the blood for producing the simultaneous effects of increasing the permeability of the blood-brain barrier and allowing the maximum passage of the exogenous molecule from the blood to the cells of the central nervous system.

(388) In other embodiments, compounds of the invention can be formulated as a prodrug with a fatty acid carrier (and optionally with another neuroactive drug). The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. The prodrug preferably has a brain penetration index of at least two times the brain penetration index of the drug alone. Once in the central nervous system, the prodrug, which preferably is inactive, is hydrolyzed into the fatty acid carrier and the provided CHD compound or analog thereof (and optionally another drug). The carrier preferably is a normal component of the central nervous system and is inactive and harmless. The compound and/or drug, once released from the fatty acid carrier, is active. Preferably, the fatty acid carrier is a partially-saturated straight chain molecule having between about 16 and 26 carbon atoms, and more preferably 20 and 24 carbon atoms. Examples of fatty acid carriers are provided in U.S. Pat. Nos. 4,939,174; 4,933,324; 5,994,932; 6,107,499; 6,258,836; and 6,407,137, the disclosures of which are incorporated herein by reference in their entirety.

(389) The administration of the agents of the present invention may be for either prophylactic or therapeutic purposes. When provided prophylactically, the agent is provided in advance of disease symptoms. The prophylactic administration of the agent serves to prevent or reduce the rate of onset of symptoms of ALS. When provided therapeutically, the agent is provided at (or shortly after) the onset of the appearance of symptoms of actual disease. In some embodiments, the therapeutic administration of the agent serves to reduce the severity and duration of the disease.

(390) The function and advantage of these and other embodiments of the present invention will be more fully understood from the examples described below. The following examples are intended to illustrate the benefits of the present invention, but do not exemplify the full scope of the invention.

EXEMPLIFICATION

(391) The foregoing has been a description of certain nonlimiting embodiments of the invention. Accordingly, it is to be understood that the embodiments of the invention herein described are merely illustrative of the application of the principles of the invention. Reference herein to details of the illustrated embodiments is not intended to limit the scope of the claims.

Example 1

Assays for Identification of Compounds that Protect Against Mutant SOD1-Induced Cytotoxicity

(392) High Throughput Assays

(393) Cultured cells are utilized to conduct high throughput assays for compounds that protect against mutant SOD1-induced cytotoxicity. Two assays are used: first, in the cytotoxicity protection assay, compounds are screened for their ability to protect cells from the cytotoxic effects of aggregated mutant SOD1, irrespective of mechanism of drug action. Second, in the protein aggregation assay, compounds are screened for their ability to reduce aggregation of mutant SOD1. The high throughput cytotoxicity protection assay is the primary screen and compounds active in the primary screen (and their analogs) move forward into the secondary screen for protein aggregation.

(394) The high throughput cytotoxicity protection assay was carried out in PC12 cells that express mutant G93A SOD1 as a YFP fusion protein from a doxycycline-inducible promoter (Matsumoto et al., J. Cell. Biol. 2005, 171, 75). Several lines of evidence suggest that cytotoxicity of protein aggregates in ALS is due at least in part to inhibition of the proteasome (Bruijin et al., Annu. Rev. Neurosci. 2004, 27, 723-729; Cleveland et al. Nat. Rev. Neurosci. 2001, 2(11), 806). This idea was tested by examining the sensitivity of PC12 cells to SOD1 aggregates in the presence and absence of proteasome inhibitor MG132. PC12 cells expressing no SOD1, wild type SOD1, G85R SOD1 or G93A SOD1 were grown with or without MG132 (FIG. 1). Cells expressing no SOD1, wild type SOD1 and G85R SOD1 were relatively insensitive to MG132, with an IC.sub.50 of approximately 400 nM. In contrast, cells expressing G93A SOD1 were approximately 5-fold more sensitive to MG132 (IC.sub.5075 nM). In these cells, protein aggregation was detected after 24 h and loss of cell viability was detected at approximately 48 h. Qualitatively similar results were obtained with the structurally distinct proteasome inhibitor bortezomib (Velcade), suggesting that PC12 cells are indeed susceptible to proteasome inhibition and not some other effect of MG132. The ability of protein aggregates to induce cell death was examined by treating G93A SOD1-expressing cells with MG132 for 24 h, removing the MG132 by washing and assaying cell viability after another 24 h. Because the loss of cell viability was similar following MG132 removal (FIG. 1, part C), it is likely that mutant SOD1 aggregates contribute directly to cytotoxicity in PC12 cells. However, this effect is specific for G93A SOD1 suggesting that this mutant may produce higher levels of a toxic aggregated form of SOD1.

(395) Based on these results, a high throughput screen was developed for compounds that protect against the cytotoxicity of G93A SOD1 protein aggregates using geldanamycin or radicicol as a positive control. PC12 cells expressing G93A SOD1 were treated with 100 nM MG132 with or without co-treatment with geldanamycin or radicicol. The latter compounds inhibit the chaperone HSP90 and induce expression of other chaperones. As anticipated, radicicol reduced formation of protein aggregates and increased cell viability in a dose-dependent manner (FIG. 2). Statistical analysis of the data produced a Z value of 0.55, which would predict good performance as a positive control in a high throughput screen (Zhang et al., J. Biomol. Screen 1999, 4(2), 67-73).

(396) Mutant SOD1 Direct Protein Aggregation Assay.

(397) Compounds that are active in the above assay could theoretically protect against mutant SOD1-induced cytotoxicity through a number of mechanisms, including the following: 1) Compounds could nonspecifically block or reverse protein aggregation via chaperone induction, as observed for radicicol and geldanamycin 2) Compounds could block or reverse the aggregation of a specific aggregated protein form 3) Compounds could interfere with an event downstream of protein aggregation that plays a critical role in mutant SOD1-induced cytotoxicity (e.g., proteasome function). 4) Compounds could act directly on SOD1 in a manner that prevents mutant SOD1 aggregation. These possibilities were tested using an assay that directly measures protein aggregation. In addition, unlike the high throughput cytotoxicity protection assay, the protein aggregation assay is based on G85R SOD1; this broadens the scope of the screening strategy, and should eliminate compounds with highly specific activity (i.e., G93A SOD1 limited) against protein aggregation.

(398) In PC12 cells that express wild-type SOD1, SOD1 was diffusely localized throughout the cell (Matsumoto et al., J. Cell. Biol 2005, 171(1), 75-85). In contrast, G85R SOD1 showed heterogeneous patterns of localization; in most cells, G85R was diffusely localized throughout the cell, but in 5% of the cells, G85R SOD1 was localized in large peri-nuclear aggregates. In cells treated with MG132, up to 75% of cells expressing G85R SOD1 contain such protein aggregates (FIG. 3), but no aggregation was observed in cells expressing wild-type SOD1. Cells expressing G93A mutant SOD1 showed an intermediate level of protein aggregation: none of the cells developed protein aggregates in the absence of MG132, and 75% of the cells had protein aggregates following treatment with MG132 (FIG. 3). Similar effects were observed in cells treated with bortezomib (Velcade). Therefore, these effects are likely to be due to MG132-induced proteasome inhibition, and not due to an off-target effect of MG132.

(399) The sensitivity of this assay was optimized by selecting conditions that maximize the difference between active and inactive samples. The identification of a positive control is a crucial step in assay development. Thus, PC12 cells expressing G85R or G93A mutant SOD1 were treated with MG132 to induce protein aggregation, and then co-treated with candidate chemical suppressors of protein aggregation. Two compounds with similar activity were identified in these experiments: geldanamycin and radicicol. Both compounds induce heat shock transcription factor HSF-1, which in turn induces the heat shock response (FIG. 4). Treatment with radicicol reduced the proportion of cells with aggregates from 75% to 25%, a sufficient difference to allow visual scoring for compounds with efficacy equal to or greater than radicicol.

(400) To allow this assay to be used in a high-throughput manner, a Cellomics Arrayscan high content microscopy system was used for screening and quantification. Initial experiments indicated that G85R SOD1 aggregates were more readily recognized by the high content microscopy system and its computer algorithm. Because the most robust high content assays measure events on a per cell basis, it was necessary to select a fluorescent stain that marks whole cells to be used with a compatible stain that marks intracellular structures. On the basis of pilot experiments with a number of vital dyes, an Image-iT conjugated wheat germ agglutinin (WGA) dye from Molecular Probes was selected and a computer algorithm for detecting WGA was developed. As shown in FIG. 5, WGA provided an excellent cellular marker that did not interfere with detection of YFP-tagged SOD1.

Example 2

Identification of Chemical Lead(s) Whose Predicted Pharmacological Properties are Suitable for Testing in Mice

(401) The most common and most rigorous approach to determine the toxicity and pharmacological properties of candidate pharmacological compounds relies on in vivo testing in laboratory animals. Because animal testing is both expensive and time consuming, many drug discovery organizations have turned to in vitro methods to analyze the pharmacological properties of compounds during structural optimization. This approach relies on miniaturized predictive in vitro ADMET assays that are amenable to high- to medium-throughput implementation. The need for methods of this type has also been motivated by the switch from animal disease models to target based in vitro methods for lead discovery (Kerns et al. Curr. Top Med. Chem. 2002, 2(1), 87-98; Di et al., Curr. Opin. Chem. Biol. 2003, 7(3) 402-408; Kassel et al., Curr. Opin. Chem. Biol. 2004, 8(3), 339-345). The in vitro ADMET approach is based on the use of a suite of chemical tests (compound integrity, compound solubility, compound aggregation, lipophilicity, pKa) and biological assays (Caco-2 and/or PAMPA assays, cytochrome P450 metabolism and inhibition, cardiac risk, and cytotoxicity) that assess the absorption, distribution, metabolism, excretion, and toxic effects of test compounds. The output from ADMET assays is used to identify and select for compounds with low predicted toxicity and desirable predicted pharmacological properties during SAR-based optimization. Compounds optimized by this approach are selected for analysis in the mouse model of ALS. The following suite of assays are performed:

(402) Cytotoxicity is determined in cultured cells.

(403) Compound Purity:

(404) Each compound is subjected to chemical analysis to confirm molecular weight and determine purity. Only compounds >95% pure are used for further testing. Compounds <80% pure are re-purified and re-tested.

(405) Compound Aggregation:

(406) Aggregation of screening hits is measured using dynamic light scattering.

(407) Solubility:

(408) Because compounds are stored in DMSO, it is necessary to determine aqueous solubility of initial hit compounds and their analogs. High solubility in aqueous solution is necessary for high GI absorption, bioavailability, and for chemical formulation. Compounds should be soluble in aqueous solution at >10 g/ml. Solubility of >50 g/ml is preferred.

(409) General Permeability:

(410) High membrane permeability is required for effective GI absorption and optimal bioavailability. Passive permeability is typically assessed in the PAMPA artificial membrane assay (Kansy et al., J. Med. Chem. 2002, 45(8), 1712-1722). Cell-based permeability determinations using the Caco-2 cell assay are more resource intensive but more predictive of active transport or efflux in vivo (Artursson et al., Adv. Drug. Deliv. Rev. 2001, 46(1-3), 27-43). Caco-2 assays are performed as needed during SAR development.

(411) Blood Brain Barrier:

(412) CNS therapeutics must penetrate the blood-brain barrier (BBB) to achieve in vivo efficacy (Basak et al., Pharm Res. 1996, 13(5), 775-778). A QSAR model was developed for predicting in vivo BBB partitioning using the logarithm of the blood-brain concentration ratio as a diagnostic indicator. A 189 compound dataset was constructed from data in the literature (Rose et al., J. Chem. Inf. Comp. Sci. 2002, 42(3), 651-656; Pan et al., J. Chem. Inf. Comp. Sci. 2004, 44(6), 2083-2098) and compounds in the dataset entered as 2D structural drawings with ISIS/Draw and saved as mol files and converted into 3D structures using the Corina software prior to calculating molecular descriptors using Dragon. A Support Vector Machine (SVM) linear regression algorithm was used to generate & validate the model. The prediction accuracy (Q) for the SVM linear regression training model (n=166) and validation set (n=24) was 86.75 and 86.96%, respectively, confirming the validity of the model. Using this BBB predictive model, the potential of active compounds to cross the BBB is appraised early during development. Other BBB predictive models, including a variant of the PAMPA assay developed specifically for this purpose (Di et al., Eur J Med Chem. 2003, 38(3), 223-32), is used as needed. Results of these experiments guide synthesis of compounds with appropriate ADME properties for use as CNS therapeutics.

(413) Neuronal Penetration Assay:

(414) Neurons are a highly differentiated cell type, and it has been commonly observed that many chemical structures are unable to penetrate into these cells. In many embodiments, a drug used to treat a neurodegenerative disease should desirably penetrate into neurons. During the synthesis of analogs to identify a compound with desirable in vivo properties, the following compound was identified as an analog with improved potency (1.5 M) and a potential spectrum of desirable pharmacological properties:

(415) ##STR00212##

(5-(3,5-bis(trifluoromethyl)phenyl)cyclohexane-1,3-dione)

(416) 5-(3,5-Bis(trifluoromethyl)phenyl)cyclohexane-1,3-dione has an in vivo pharmacological half life of 3.5 hours, and achieves similar blood levels following IV or oral dosing, thus demonstrating good oral availability and penetration of the blood brain barrier. However, this compound had a surprisingly small volume of distribution in vivo and was therefore tested for neuronal penetration.

(417) A neuronal penetration assay was developed as follows. 5-(3,5-Bis(trifluoromethyl)phenyl)cyclohexane-1,3-dione protects cultured PC12 cells from the toxic effects of MG132. In order to determine if this compound could protect primary cortical neurons from MG132 toxicity primary cortical neurons were treated with a toxic dose of MG132 together with various concentrations of 5-(3,5-bis(trifluoromethyl)phenyl)cyclohexane-1,3-dione. As shown in FIG. 6, no dose of this compound was effective in protecting the primary cortical neurons, suggesting that penetration into these cells was limited. Analogs of 5-(3,5-bis(trifluoromethyl)phenyl)cyclohexane-1,3-dione were then prepared and tested to determine whether chemical modifications would lead to a compound with neuronal cell penetrating ability. As shown in FIG. 6, two of the tested analogs were active. Demonstration of activity in this assay confirms, among other things, that the compounds penetrate neurons. As summarized in Table 2 below, these analogs also retained protective activity against mutant SOD1 toxicity. These results further confirm the previous understanding based on the collective data that certain of the provided compounds readily cross the BBB, penetrate neurons, and protect against mutant SOD1 toxicity.

(418) Some of the potential chemical properties needed to achieve both cortical neuron penetration and protection against mutant SOD1 toxicity were identified in these structure activity studies. Based on the data set in Table 2, and without wishing to be bound by any particular theory, it appears that in certain instances direct attachment of the aromatic ring to the cyclohexane-1,3-dione ring is less favorable for neuronal penetration than a two-unit linker.

(419) TABLE-US-00002 TABLE 2 List of compounds with and without primary cortical neuron efficiency. Different PC12 from control Protection Assay Structure at 5 SD* (Average EC.sub.50) YES ~3.5 M NO ~1.5 M NO ~1.5 M YES ~4.0 M *5 SD = Standard Deviation (5).

(420) Lipophilicity and pKa:

(421) Lipophilicity is determined via octanol-water partition at pH 7.4 (Hitzel et al., Pharm Res. 2000, 17(11), 1389-95) and pKa is determined by capillary electrophoresis and photodiode array detection (Ishihama et al., J Pharm Sci. 2002. 91(4), 933-42).

(422) Metabolism (Microsome, S9 Fraction, CYP450):

(423) Liver Cytochrome P450 (CYP450) enzymes are the major route for xenobiotic metabolism and microsomal and hepatocyte stability is the best predictor of pharmacokinetic half-life. Cross-species comparisons of metabolism in liver microsomes can predict potential issues with liver toxicity in humans. Selected active compounds are tested in liver microsomes from efficacy species (mouse), toxicity species (rat, dog, monkey), and humans for metabolic stability.

(424) Drug-Drug Interaction and Cardiac Risk Potential:

(425) Data-mining algorithms and data compiled from the literature, are used to predict whether active compounds are likely to interact with and/or inhibit major Cytochrome P450's (1A2, 2C9. 2 C19, 3A4, 2D6) (Kerns et al., Curr Top Med Chem. 2002, 2(1), 87-98). Synthesized compounds are also tested directly for ability to bind and inhibit human CYP P450. If potential problems are indicated by these approaches, analog synthesis is directed towards developing alternative compounds. This approach allows for the assessment of cardiac safety, since hERG inhibition is assessed simultaneously on the same compounds. The hERG assay is done with the fast-patch methodology. hERG ion channel inhibition is implicated in greater than 90% of reported cases of cardiac toxicity, and is a common cause of after market drug failures and withdrawals. Information on hERG inhibition as well as inhibition of five major human CYP450s (1A2, 2C9. 2 C19, 3A4, 2D6) allows for accurate prediction of potential drug-associated cardiac risk.

(426) Plasma Stability:

(427) Plasma stability of active compounds is assessed in efficacy species (mouse), toxicity species (rat, dog, monkey), and human cells.

(428) Plasma Protein Binding:

(429) Plasma protein binding is examined in efficacy species (mouse), toxicity species (rat, dog, monkey), and human cells using ultrafiltration methodology.

(430) Results:

(431) The following results were obtained for the provided CHD compound shown below.

(432) Pharmacokinetic Properties:

(433) TABLE-US-00003 Potency (EC.sub.50): 0.70 M Solubility: 500 M Human Metabolic Potential: low (T.sub.1/2 = >180 min) Mouse Metabolic Potential: low (T.sub.1/2 = >180 min) Plasma Stability: medium Caco-2: high predicted permeability (A B = 38 cm/s)

(434) The compounds identified are evaluated in the transgenic G93A ALS mouse model. ADME data is used to determine optimal route of administration. LD.sub.50 and maximally-tolerated dose are determined, and that information is used to design and execute pharmacokinetic studies to assess brain bioavailability, and to guide choice of dosing regimen (i.e., frequency, dose, route). Three-dose basic efficacy studies are performed on compounds demonstrating acceptable tolerability and bioavailability. For compounds that demonstrate efficacy, a more complete preclinical study is performed and the efficacies of the test compound and previously characterized neuroprotective agents are compared. In certain embodiments, this includes further dose optimization, phenotype assessment, comparison with compounds of established efficacy, and analysis of brain tissue in treated animals.

Example 3

Identification and Characterization of Lead CHD Compounds Using in Vitro ADMET Assays and In Vivo Efficacy Studies

(435) The present Example describes identification and characterization of CHD compounds, and in particular of CHD compounds that are active in both protection and aggregation assays. Some CHD compounds described herein show EC.sub.50s below 10, 9, 8, 6, 5, 4, 3, 2, 1 micromolar or less. Some CHD compounds described herein show EC.sub.50s within the 1-2 micromolar range. Some such CHD compounds described herein show 100% protection. Some such CHD compounds described herein show little or no detectable cytotoxicity at 100 micromolar concentrations.

(436) In Vitro ADME Study of CHD Compounds.

(437) Provided CHD compounds are evaluated for their in vitro ADME properties.

(438) Preliminary Blood Brain Barrier (BBB) Penetration Experiment.

(439) An in vivo BBB penetration experiment is carried out for the CHD scaffold.

(440) Procedures

(441) Subjects.

(442) In the present study, G93A SOD1 mice and littermate controls are bred from existing colonies at the Bedford VA Medical Hospital. The male G93A SOD1 mice are mated with B6SJL females and the offspring are genotyped by PCR using tail DNA. The number of SOD1 transgenes are assessed periodically by PCR to ensure that transgene copy number does not increase or decrease significantly over the course of time. Mice are housed in micro-isolator cages in complete barrier facilities. A 12 hour light-dark cycle is maintained and animals are given free access to food and water. Control and transgenic mice of the same age (2 days) and from the same f generation are selected from multiple litters to form experimental cohorts (n=20 per group). Standardized criteria for age and parentage are used for placing individual mice into experimental groups/cohorts. Wild type mice are used for initial toxicity, tolerability, and pharmacokinetic studies and ALS mice are used for one month tolerability studies.

(443) Tolerability, Dosing, and Pharmacokinetics.

(444) The tolerable dose range and LD50 for each test compound is determined in wild type mice by increasing the dose b.i.d. one-fold each injection. The route of administration (p.o. by gavage or i.p.) and starting dose is based on solubility and other output from ADME studies. Initial pharmacokinetic (pK) studies are conducted by giving animals a single dose, sacrificing them after 30 min, 1 h, 2 h, 4 h, 6 h, or 12 h, and dissecting brains and spinal cords and determining drug concentration in the target tissue. Drug steady-state level are determined in animals that have been dosed for 1 week prior to sacrifice. These data are used to optimize the dosing regimen for efficacy studies. Drug doses should achieve a desirable drug concentration in the brain and spinal cord of treated mice. Working doses at least 10-fold lower than the acute tolerability dose are preferable.

(445) Efficacy Studies.

(446) Efficacy is measured using endpoints that clearly indicate neuroprotective function. These include amelioration of degenerative changes in the spinal cord, improved motor function, and prolonged survival. Some mice cohorts are sacrificed at a predetermined time point (120 days) for neuropathological examination, while others are sacrificed at end stage disease using criteria for euthanasia. The latter cohorts are followed temporally for behavioral analyses as well as survival.

(447) Survival.

(448) Mice are observed three times daily (morning, noon, and late afternoon) throughout the experiment. Mice are euthanized when disease progression was sufficiently severe that they are unable to initiate movement and right themselves after gentle prodding for 30 seconds.

(449) Body Weights.

(450) Mice are weighed twice a week at the same time each day. Weight loss is a sensitive measure of disease progression in transgenic G93A SOD1 mice and of toxicity in transgenic and wild type mice.

(451) Motor/Behavioral.

(452) Quantitative methods of testing motor function are used including Rotarod and analysis of open field behavior. Decline of motor function is a sensitive measure of disease onset and progression. Behavioral testing for the transgenic G93A SOD1 mice is performed during the light phase of the diurnal cycle since these mice are sufficiently active during that time. Measurements are made for 30 minutes after 10 minutes of acclimation to the box (Opto-Varimex Unit, Columbus Instruments, Columbus, Ohio, USA). Counts of horizontal and vertical motion activity are monitored and quantitative analysis of locomotor activity (resting and ambulatory times) is assessed. The open field box is cleaned before testing each mouse. Each 30 minutes of testing is analyzed as three periods of 10 minute intervals to study the influence of novelty and measured behavior. Mice are coded and investigators are blinded to the genotype and analysis. Testing starts on week 4 and is performed every other week until the mice can no longer participate.

(453) Neuropathology.

(454) Selected cohorts (n=10) of treated and untreated G93A SOD1 mice are euthanized at 120 days for isolation and analysis of spinal cord tissue. For this purpose, mice are deeply anesthetized and perfused transcardially with 4% buffered paraformaldehyde at the desired time point. These studies are performed in a blinded manner, to avoid bias in interpretation of the results. Brains are weighed, serially sectioned at 50 pm and stained for quantitative morphology (cresyl violet) to determine gross atrophy and identify ventral neuron loss and astrogliosis. Remaining tissue samples/sections are stored for future use. Stereology is used to quantify gross ventral horn atrophy, neuronal atrophy, and neuronal loss. Remaining tissue samples/sections are stored for prospective mechanistic analyses as necessary.

(455) Analysis.

(456) Data sets are generated and analyzed for each clinical and neuropathological measure. Effects on behavior and neuropathology are compared in treatment and control groups. Dose-dependent effects are assessed in each treatment group using multiple two-sided ANOVA tests. Multiple comparisons in the same subject groups are dealt with post hoc. Kaplan-Meier analysis is used for survival and behavioral function.

(457) Neuronal Quantitation.

(458) Serial lumbar spinal cord tissue sections (n=20) from L3-L5 spinal cord segments are used for gross spinal cord areas and neuronal analysis. Gross areas of the spinal cord sections are quantified from each experimental cohort using NIH Image. From the same sections, the ventral horn is delineated by a line from the central canal laterally and circumscribing the belly of gray matter. Absolute neuronal counts of Nissl-positive neurons are performed in the ventral horns in the lumbar spinal cord. Only those neurons with nuclei are counted. All counts are performed with the experimenter blinded to treatment conditions. Counts are performed using Image J (NIH) and manually verified and the data represent the average neuronal number from the sections used.

(459) Interpretation.

(460) Compound efficacy is evaluated using behavioral and neuropathological endpoints. Results for the test compound are compared with results from compounds with established efficacy and neuroprotective action in the G93A SOD1 mouse model. These experiments directly test whether provided compounds provide therapeutic benefit and, if so, the magnitude of the benefit. Along the way, useful information about solubility, administration, and toxicity are also obtained.

Example 4

Synthesis of Provided CHD Compounds

(461) Provided compounds may be prepared by methods known to one of ordinary skill in the art and/or by methods illustrated in Scheme 1, below. Where a particular protecting group, leaving group, or transformation condition is depicted, one of ordinary skill in the art will appreciate that other protecting groups, leaving groups, and transformation conditions are also suitable and are contemplated. Such groups and transformations are described in detail in March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 5.sup.th Edition, John Wiley & Sons, 2001, Comprehensive Organic Transformations, R. C. Larock, 2.sup.nd Edition, John Wiley & Sons, 1999, and Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3.sup.rd edition, John Wiley & Sons, 1999, the entirety of each of which is hereby incorporated herein by reference.

(462) ##STR00218##

(463) As depicted above in Scheme 1, provided compounds can be synthesized from a variety of commercially available or previously prepared benzaldehyde derivatives. Olefination of benzaldehyde E-1 with a suitable phosphonium ylid affords ,-unsaturated ketone E-2. E-2 can then undergo cyclization under basic conditions (e.g., using an alkoxide base) with a suitable malonate derivative (e.g., diethylmalonate) to afford the desired product E-3.

(464) ##STR00219##

(465) As depicted above in Scheme 2, provided compounds can be synthesized from a variety of commercially available or previously prepared benzaldehyde or 2-phenylacetaldehyde derivatives. Olefination of benzaldehyde E-1 or phenylacetaldehyde E-4 with a suitable phosphonium ylid affords ,-unsaturated ketone E-5. E-5 can then undergo cyclization under basic conditions (e.g., using an alkoxide base) with a suitable malonate derivative (e.g., diethylmalonate) to afford the desired product E-6.

(466) ##STR00220##

(467) As depicted above in Scheme 3, provided compounds can be synthesized from a variety of commercially available or previously prepared hydroxybenzoate derivatives. o-Alkylation of hydroxybenzoate E-7 with a suitable alkylating reagent (e.g., (3-bromopropyl)benzene) affords ether E-8. E-8 can then be transformed under suitable conditions in one or more steps to the desired benzaldehyde E-9. E-9 can be a test compound or can be further modified (e.g., via reaction with a suitable amine, Wittig reaction and/or a modification thereof selective for either the E or Z isomer, reduction, nucleophilic addition, etc.) to provide a test compound.

(468) ##STR00221##

(469) As depicted above in Scheme 4, (R)- and (S)-1-(3,5-bis(trifluoromethyl)phenoxy)ethanol were synthesized from phenol E-10. Upon exposure to a suitable alkylating reagent, phenol E-10 was o-alkylated to afford ether E-11. The ethyl ester of E-11 was then reduced in the presence of a suitable reducing agent (e.g., a metal hydride such as LiAlH.sub.4) to the corresponding alcohol E-12. Acylation of racemic E-12 upon exposure to a suitable chiral derivative (e.g., (S)-campanic chloride) provided the corresponding ester as a diastereomeric mixture separable by column chromatography. Subsequent saponification of acylated E-12 provided compounds E-13a and E-13b.

(470) ##STR00222##

(471) Alternatively, as depicted above in Scheme 5, one of skill in the art would appreciate that the steps of reduction and resolution can be reversed. For instance, one of skill in the art could envision accessing either of E-13a or E-13b by exposing the corresponding chiral precursor E-14a or E-14b to a suitable reducing agent (e.g., LiAlH.sub.4). E-13a and E-13b can then be oxidized using a suitable oxidant to afford the corresponding aldehydes, which can be taken on as shown in Scheme 1 (above) to provide chiral compounds E-15a and E-15b.

EQUIVALENTS

(472) Having described some illustrative embodiments of the invention, it should be apparent to those skilled in the art that the foregoing is merely illustrative and not limiting, having been presented by way of example only. Numerous modifications and other illustrative embodiments are within the scope of one of ordinary skill in the art and are contemplated as falling within the scope of the invention. In particular, although many of the examples presented herein involve specific combinations of method acts or system elements, it should be understood that those acts and those elements may be combined in other ways to accomplish the same objectives. Acts, elements, and features discussed only in connection with one embodiment are not intended to be excluded from a similar role in other embodiments. Further, for the one or more means-plus-function limitations recited in the following claims, the means are not intended to be limited to the means disclosed herein for performing the recited function, but are intended to cover in scope any means, known now or later developed, for performing the recited function.

(473) Use of ordinal terms such as first, second, third, etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements. Similarly, use of a), b), etc., or i), ii), etc. does not by itself connote any priority, precedence, or order of steps in the claims. Similarly, the use of these terms in the specification does not by itself connote any required priority, precedence, or order.

(474) The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.